BLOOD CANCER UNITED INC: Form 990, tax year 2014
View the entire original 990 at ProPublica ↗
- Organization
- BLOOD CANCER UNITED INC (EIN 13-5644916)
- Tax period
- 2014-07-01 to 2015-06-30
- Filed
- 2016-02-11
- IRS object ID
- 201620429349300232
- Schema version
- 2014v6.0
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule C
- Schedule D
- Schedule F
- Schedule G
- Schedule I
- Schedule J
- Schedule M
- Schedule O
- Schedule R
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2016-02-11T09:16:30-06:00 | ReturnTs |
| Tax Period End | 2015-06-30 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 135565207 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | KPMG LLP | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 345 PARK AVENUE | AddressLine1Txt |
| City | NEW YORK | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 101540102 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2014-07-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 135644916 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | THE LEUKEMIA & LYMPHOMA SOCIETYINC | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | LEUK | BusinessNameControlTxt |
| Phone | 9149495213 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1311 MAMARONECK AVENUE - SUITE 310 | AddressLine1Txt |
| City | WHITE PLAINS | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 10605 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | ROSEMARIE LOFFREDO | PersonNm |
| Person Title | EVP - CAO & CFO | PersonTitleTxt |
| Phone | 9149495213 | PhoneNum |
| Signature | 2016-02-09 | SignatureDt |
| Discuss With Paid Preparer | Yes (true) | DiscussWithPaidPreparerInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | KPMG LLP | PreparerPersonNm |
| PTIN | P01249521 | PTIN |
| Phone | 2127589700 | PhoneNum |
| Preparation | 2016-02-11 | PreparationDt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2014 | TaxYr |
| Build TS | 2016-08-17 19:52:53Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | LOUIS J DEGENNARO PRESIDENT CEO | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1311 MAMARONECK AVENUE | AddressLine1Txt |
| City | WHITE PLAINS | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 10605 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $387,950,949 | GrossReceiptsAmt |
| Group Return For Affiliates | false | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | WWW.LLS.ORG | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 1949 | FormationYr |
| Legal Domicile State | NY | LegalDomicileStateCd |
| Activity Or Mission | OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES. | ActivityOrMissionDesc |
| Voting Members Governing Body | 29 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 29 | VotingMembersIndependentCnt |
| Total Employee | 1321 | TotalEmployeeCnt |
| Total Volunteers | 3000000 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| PY Contributions Grants | $302,437,152 | PYContributionsGrantsAmt |
| CY Contributions Grants | $283,909,984 | CYContributionsGrantsAmt |
| CY Program Service Revenue | $0 | CYProgramServiceRevenueAmt |
| PY Investment Income | $6,995,117 | PYInvestmentIncomeAmt |
| CY Investment Income | $4,913,321 | CYInvestmentIncomeAmt |
| PY Other Revenue | $663,718 | PYOtherRevenueAmt |
| CY Other Revenue | -$7,194,375 | CYOtherRevenueAmt |
| PY Total Revenue | $310,095,987 | PYTotalRevenueAmt |
| CY Total Revenue | $281,628,930 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $130,249,475 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $107,996,054 | CYGrantsAndSimilarPaidAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $94,185,722 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $85,679,493 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $7,178,370 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $4,709,809 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $42,413,663 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $85,584,715 | PYOtherExpensesAmt |
| CY Other Expenses | $79,057,701 | CYOtherExpensesAmt |
| PY Total Expenses | $317,198,282 | PYTotalExpensesAmt |
| CY Total Expenses | $277,443,057 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | -$7,102,295 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | $4,185,873 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $242,581,527 | TotalAssetsBOYAmt |
| Total Assets EOY | $214,485,806 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $145,444,419 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $116,963,860 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $97,137,108 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $97,521,946 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES. | MissionDesc |
| Significant New Program Srvc | false | SignificantNewProgramSrvcInd |
| Significant Change | false | SignificantChangeInd |
| Expense | $69,238,255 | ExpenseAmt |
| Grant | $65,760,793 | GrantAmt |
| Desc | A) RESEARCH PROGRAMS: WITH ADVISORY INPUT FROM RECOGNIZED BIOMEDICAL RESEARCH EXPERTS, LLS FUNDS EXEMPLARY PROJECTS ACROSS THE ENTIRE RESEARCH CONTINUUM RELEVANT TO IMPROVED OUTCOMES FOR BLOOD CANCER PATIENTS, FROM BASIC LABORATORY SCIENCE THROUGH CLINICAL TRIALS, AND FROM INVESTIGATOR-INITIATED RESEARCH TO PRIVATE-SECTOR DRUG DEVELOPMENT ALLIANCES. LLS IS DELIBERATE AND PURPOSEFUL IN FINDING AND SUPPORTING RESEARCH THAT IS MOST LIKELY TO HELP PATIENTS AS SOON AS POSSIBLE. TO DATE, LLS HAS INVESTED OVER 1 BILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. WE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2015, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 7 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 65 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, AND, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. - ADCETRIS WAS APPROVED IN 2011, AND IN JANUARY 2012. IT IS AN ANTIBODY- DRUG CONJUGATE THAT COMBINES AN ANTI-CD30 ANTIBODY AND THE CYTOTOXIC DRUG MONOMETHYL AURISTATIN E (MMAE). IT IS AN ANTI-NEOPLASTIC AGENT USED IN THE TREATMENT OF HODGKIN LYMPHOMA AFTER FAILURE OF AUTOLOGOUS STEM CELL TRANSPLANT OR THOSE WHO ARE NOT ELIGIBLE FOR ASCT AFTER FAILURE OF AT LEAST 2 MUTIAGEN CHEMOTHERAPY REGIMENS. ADCETRIS WAS ALSO APPROVED FOR SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA WITH FAILURE OF AT LEAST ONE PRIOR TREATMENT. - GAZYVA IS A HUMANIZED MONOCLONAL ANTIBODY USED AS A COMBINATION TREATMENT WITH CHLORAMBUCIL TO TREAT PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA. IT WAS APPROVED BY THE FDA IN NOVEMBER 2013 AND BY THE EHA IN JULY 2014. - IMBRUVICA IS AN ORAL SMALL MOLECULE INHIBITOR AGIANST BTK KINASE. IT WAS FIRST APPROVED BY THE US FDA ON NOVEMBER 13, 2013 FOR THE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS WHO HAVE RECIEVED AT LEAST ONE PRIOR TREATMENT. ON FEB. 12, 2014 THE US FDA EXPANDED THE APPROVED USE OF THE DRUG TO CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ADDITIONALLY, IT RECEIVED FURTHER EXPANSION TO TREAT 17P DELETION IN CLL WITH OR WITHOUT PRIOR THERAPY. - ZYDELIG IS AN ORAL SMALL MOLECULE INHIBITOR THAT BLOCKS THE DELTA ISOFORM OF THE ENZYME PHOSPHOINOSITIDE 3-KINASE. IT WAS APPROVED BY THE FDA IN JULY 2014 TO TREAT RELAPSED/REFRACTORY CLL IN COMBINATION WITH RITUXAN. IT WAS ALSO APPROVED TO USE AS A MONOTHERAPY FOR RELAPSED MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2015, FOR THE FOURTH YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN SIX OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES FOR PATIENTS WITH NON- CUTANEOUS T-CELL LYMPHOPROLIFERATIVE DISORDERS - DEVELOP NOVEL TARGETED THERAPIES FOR CLL PATIENTS, WITH REAL CURATIVE POTENTIAL - DEVELOP NOVEL TREATMENT STRATEGIES FOR MDS AND AML PATIENTS - DEVELOP NOVEL TARGETED THERAPIES FOR PATIENTS WITH HIGH-RISK MYELOMA - DEVELOPMENT OF NEW-TARGETED THERAPIES FOR INDOLENT LYMPHOMA PATIENTS - DEFINE GENETIC/MOLECULAR PREDISPOSITIONS TO LONG-TERM AND LATE- | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $86,747,069 | ExpenseAmt |
| Grant | $42,235,261 | GrantAmt |
| Desc | B) PATIENT & COMMUNITY SERVICES: AN ESTIMATED 1.2 MILLION PEOPLE ACROSS THE UNITED STATES (US) CURRENTLY BATTLE LEUKEMIA, LYMPHOMA AND MYELOMA. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) OFFERS A FREE, COMPREHENSIVE ARRAY OF SERVICES TO BLOOD CANCER PATIENTS AND THEIR FAMILIES, VOLUNTEER CAREGIVERS AND ADVOCATES, HEALTHCARE PROFESSIONALS AND THE PUBLIC. LLS IS COMMITTED TO PROVIDING THE MOST ACCURATE AND UP-TO-DATE BLOOD CANCER INFORMATION. PROFESSIONAL VOLUNTEER CLINICAL ADVISORS WORK WITH LLS STAFF TO REVIEW ALL OF THE INFORMATION LLS PROVIDES THROUGH HEALTHCARE PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE LLS WEBSITE. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL; AND CURRENT AND ACCURATE INFORMATION ABOUT SYMPTOMS, RISK FACTORS AND TREATMENT. PUBLICATIONS AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS THROUGH THE INFORMATION RESOURCE CENTER AND LLS CHAPTERS. MANY MATERIALS ARE ALSO AVAILABLE TO VIEW AND DOWNLOAD AT WWW.LLS.ORG/RESOURCECENTER. DOWNLOADABLE MATERIALS ARE AVAILABLE IN ENGLISH, SPANISH AND FRENCH. - 705,326 PRINTED BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS DISTRIBUTED IN 2015. FINANCIAL ASSISTANCE IN 2015, A COMBINED 42,235,261 WAS DISBURSED TO PATIENTS THROUGH THE LLS PATIENT FINANCIAL AID (111,525),CO-PAY ASSISTANCE PROGRAMS (41,805,481) AND THE LLS NATIONAL PATIENT TRAVEL ASSISTANCE PROGRAM (318,255). CO-PAY ASSISTANCE PROGRAM THIS CO-PAY ASSISTANCE PROGRAM HELPS PATIENTS WITH MANY KINDS OF BLOOD CANCERS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO-PAYMENT OBLIGATIONS RELATED TO TREATING THEIR CANCER. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUND AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. FOR MORE INFORMATION CALL, (877) LLS-COPAY (877) 557-2672 OR VISIT WWW.LLS.ORG/COPAY. - 19,922 PATIENTS RECEIVED LLS CO-PAY ASSISTANCE IN 2015 COMMUNITY PROGRAMS EACH LLS CHAPTER OFFICE IS STAFFED WITH A PATIENT SERVICES MANAGER (PSM) WHO OVERSEES SERVICES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PSMS ARE HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING OR SOCIAL WORK. PSMS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS. COMMUNITY-BASED EDUCATION AND OUTREACH, SUPPORT AND PUBLIC POLICY AND ADVOCACY PROGRAMS ARE AVAILABLE. PATIENT EDUCATION PROGRAMS: IN 2015 WE CONDUCTED 221 LOCAL PATIENT EDUCATION PROGRAMS TO A TOTAL OF 9,807 ATTENDEES. THESE PROGRAMS RANGED FROM DISEASE SPECIFIC TOPICS TO THOSE OF SURVIVORSHIP. OF THE TOTAL ATTENDING THESE LOCAL EDUCATION PROGRAMS, A MAJORITY WERE PATIENTS AND CAREGIVERS (6,872 ATTENDEES) BUT IMPORTANTLY, MANY (2,404 ATTENDEES) WERE HEALTHCARE PROFESSIONALS. BLOOD CANCER CONFERENCES: LLS WORKS TO ELEVATE OUR VISIBILITY IN COMMUNITIES WE SERVE BY HOSTING LARGER-SCALE CONFERENCES, GEARED FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. THESE EVENTS ARE A CATALYST FOR BRINGING MANY DEDICATED PEOPLE TOGETHER TO FOCUS ON BLOOD CANCER AWARENESS, INFORMATION AND THE LATEST ADVANCES IN MEDICAL SCIENCE. THEY ARE ALSO AN IMPORTANT SOURCE OF CONTINUING EDUCATION FOR MANY HEALTHCARE PROFESSIONALS. IN 2015, 25 BCC CONFERENCES WERE HELD WITH TOTAL ATTENDANCE OF 6,589. 2,965 WERE PATIENTS, 1,511 CAREGIVERS, 1,001 NURSES, 181 SOCIAL WORKS, 128 MEDICAL DOCTORS, AND 628 "OTHER" HEALTHCARE PROFESSIONALS SERVING THE UNDERSERVED: IN 2015, WE OFFERED 68 SPECIAL PROGRAMS TO PEOPLE WHO OFTEN DON'T HAVE THE SAME ACCESS TO INFORMATION AND SUPPORT AS OTHERS MIGHT HAVE. BREAKING DOWN ACCESS BARRIERS IN UNDERREPRESENTED POPULATIONS MEANS BLOOD CANCER PATIENTS GET THE INFORMATION AND SUPPORT THEY NEED. THIS OUTREACH BROUGHT IMPORTANT DISEASE TREATMENT INFORMATION TO MORE THAN 5,500 PEOPLE IN COMMUNITIES WE SERVE. OF THIS, 3,870 WERE PATIENTS AND CAREGIVERS, JOINED BY 1,126 HEALTHCARE PROFESSIONALS. MYELOPROLIFERATIVE NEOPLASMS OR MPN: IN 2015, LLS WAS ABLE TO OFFER SPECIALIZED MYELOPROLIFERATIVE NEOPLASMS OR MPN EDUCATION PROGRAMS IN FOUR COMMUNITIES TO A TOTAL OF 70 PATIENTS AND CAREGIVERS AND 9 HEALTHCARE PROFESSIONALS. IN ADDITION, LLS PROVIDED COMMUNITY-BASED EDUCATION CONCERNING THE LATEST CLINICAL TRIALS INFORMATION TO 634 PATIENTS AND CAREGIVERS, WHO WERE JOINED BY 286 HEALTHCARE PROFESSIONALS. FAMILY SUPPORT GROUPS: THROUGHOUT THE US, IN 2015, LLS SUPPORTED OR HOSTED 296 REGISTERED FAMILY SUPPORT GROUP MEETINGS FOR PATIENTS AND THEIR FAMILIES. GROUPS ARE GUIDED BY TWO VOLUNTEER ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. LLS SUPPORT GROUPS ARE THE PERFECT PLACE TO TALK WITH OTHER PEOPLE AFFECTED BY BLOOD CANCERS, INCLUDING PATIENTS, FAMILY MEMBERS AND CAREGIVERS. THE GROUPS PROVIDE MUTUAL SUPPORT AND OFFER THE OPPORTUNITY TO DISCUSS ANXIETIES AND CONCERNS WITH OTHERS WHO SHARE THE SAME EXPERIENCES. THIS SHARING STRENGTHENS THE FAMILY BOND AND ENHANCES EVERYONE'S ABILITY TO COPE WITH CANCER. PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM: FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT-VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE NEW PATIENT TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS. - 1,476 FIRST CONNECTIONS ACROSS THE US IN 2015. | Desc |
Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $33,246,948 | ExpenseAmt |
| Desc | C) PUBLIC HEALTH EDUCATION: INFORMATION AND EDUCATION. INFORMATION RESOURCE CENTER. PAYING FOR MEDICAL CARE, MAKING TREATMENT CHOICES, COMMUNICATING WITH HEALTHCARE PROVIDERS, FAMILY MEMBERS AND FRIENDS-THESE ARE SOME OF THE STRESSES THAT COME WITH A CANCER DIAGNOSIS. LLS INFORMATION SPECIALISTS ARE MASTER'S LEVEL ONCOLOGY SOCIAL WORKERS, NURSES AND HEALTH EDUCATORS WHO PROVIDE HELP WITH DISEASE, TREATMENT AND CLINICAL TRIAL INFORMATION AND SUPPORT. LLS INFORMATION SPECIALISTS CONDUCT CLINICAL-TRIAL SEARCHES TO HELP PATIENTS WORK WITH THEIR DOCTORS TO FIND OUT ABOUT SPECIFIC CLINICAL TRIALS. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 9 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. - 31,511 INQUIRIES MADE TO OUR INFORMATION SPECIALISTS, AND 30,871 INQUIRIES MADE TO OUR PATIENT ACCESS STAFF ACROSS THE COUNTRY IN 2015. THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO THEIR LOCATION TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING CO-PAY ASSISTANCE, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH AND SPANISH, AND CLINICAL-TRIAL SEARCHES VIA AN ONLINE CLINICAL- TRIAL SEARCH SERVICE THAT OFFERS PATIENTS AND CAREGIVERS IMMEDIATE ACCESS TO LISTINGS OF BLOOD CANCER CLINICAL TRIALS. PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS CAN INTERACT WITH LLS AND ONE ANOTHER THROUGH SOCIAL NETWORKING, PODCASTS AND ENEWSLETTERS. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS LLS SPONSORS TELEPHONE AND WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES. IN 2015, 9 LLS NATIONAL EDUCATION PROGRAMS FEATURED DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT SUPPORT AND TREATMENT OPTIONS FROM WORLD RENOWNED CLINICAL EXPERTS. OPPORTUNITIES ARE PROVIDED TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. THESE PROGRAMS OFFER CONTINUING EDUCATION CREDITS FOR NURSES AND SOCIAL WORKERS. LLS ALSO SPONSORS A RANGE OF PROFESSIONAL EDUCATION PROGRAMS. RECENT PROGRAMS EXPLORED THE ADMINISTRATION AND MANAGEMENT OF CURRENT THERAPIES FOR HEMATOLOGIC MALIGNANCIES AND COMMUNICATION AMONG PRIMARY CARE PROVIDERS AND HEMATOLOGISTS/ONCOLOGISTS IN MANAGING PATIENTS WITH HEMATOLOGIC CANCER. UPCOMING PROGRAMS ARE POSTED AT WWW.LLS.ORG/PROGRAMS AND ARCHIVES OF PAST PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PASTPROGRAMS. PROFESSIONAL EDUCATION PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PROFESSIONALED. LLS ALSO OFFERS DISEASE-SPECIFIC WEBCASTS PRESENTED BY WORLD RENOWNED CLINICAL EXPERTS. THESE CAN BE ACCESSED AT WWW.LLS.ORG/WEBCASTS. | Desc |
Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $16,562,341 | ExpenseAmt |
| Desc | D) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Prog Srvc Expense | $16,562,341 | TotalOtherProgSrvcExpenseAmt |
| Total Program Service Expenses | $205,794,613 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (true) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (true) | ScheduleBRequiredInd |
| Political Campaign Acty | false | PoliticalCampaignActyInd |
| Lobbying Activities | Yes (true) | LobbyingActivitiesInd |
| Subject To Proxy Tax | false | SubjectToProxyTaxInd |
| Donor Advised Fund | false | DonorAdvisedFundInd |
| Conservation Easements | false | ConservationEasementsInd |
| Collections Of Art | Yes (true) | CollectionsOfArtInd |
| Credit Counseling | false | CreditCounselingInd |
| Temp Or Permanent Endowments | Yes (true) | TempOrPermanentEndowmentsInd |
| Report Land Building Equipment | Yes (true) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | Yes (true) | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | false | ReportProgramRelatedInvstInd |
| Report Other Assets | false | ReportOtherAssetsInd |
| Report Other Liabilities | false | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | Yes (true) | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | false | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | Yes (true) | ConsolidatedAuditFinclStmtInd |
| School Operating | false | SchoolOperatingInd |
| Foreign Office | Yes (true) | ForeignOfficeInd |
| Foreign Activities | Yes (true) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (true) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | false | MoreThan5000KToIndividualsInd |
| Professional Fundraising | Yes (true) | ProfessionalFundraisingInd |
| Fundraising Activities | Yes (true) | FundraisingActivitiesInd |
| Gaming Activities | Yes (true) | GamingActivitiesInd |
| Operate Hospital | false | OperateHospitalInd |
| Grants To Organizations | Yes (true) | GrantsToOrganizationsInd |
| Grants To Individuals | Yes (true) | GrantsToIndividualsInd |
| Schedule J Required | Yes (true) | ScheduleJRequiredInd |
| Tax Exempt Bonds | false | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | false | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | false | PYExcessBenefitTransInd |
| Loan Outstanding | false | LoanOutstandingInd |
| Grant To Related Person | false | GrantToRelatedPersonInd |
| Business Rln With Org Mem | false | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | false | BusinessRlnWithFamMemInd |
| Business Rln With Officer Ent | false | BusinessRlnWithOfficerEntInd |
| Deductible Non Cash Contri | Yes (true) | DeductibleNonCashContriInd |
| Deductible Art Contribution | false | DeductibleArtContributionInd |
| Terminate Operations | false | TerminateOperationsInd |
| Partial Liquidation | false | PartialLiquidationInd |
| Disregarded Entity | false | DisregardedEntityInd |
| Related Entity | Yes (true) | RelatedEntityInd |
| Related Organization Ctrl Ent | Yes (true) | RelatedOrganizationCtrlEntInd |
| Transaction With Control Ent | Yes (true) | TransactionWithControlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | false | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | false | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (true) | ScheduleORequiredInd |
| IRP Document | 845 | IRPDocumentCnt |
| IRP Document W2 G | 23 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (true) | BackupWthldComplianceInd |
| Employee | 1321 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (true) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | false | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | Yes (true) | ForeignFinancialAccountInd |
| Foreign Country | CA | ForeignCountryCd |
| Prohibited Tax Shelter Trans | false | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | false | TaxablePartyNotificationInd |
| Nondeductible Contributions | false | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | Yes (true) | QuidProQuoContributionsInd |
| Quid Pro Quo Contri Discl | Yes (true) | QuidProQuoContriDisclInd |
| Form8282 Property Disposed Of | false | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | false | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | false | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | false | IndoorTanningServicesInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 29 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 29 | IndependentVotingMemberCnt |
| Family Or Business Rln | false | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | false | DelegationOfMgmtDutiesInd |
| Change To Org Documents | false | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | false | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | Yes (true) | MembersOrStockholdersInd |
| Election Of Board Members | Yes (true) | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | Yes (true) | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (true) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (true) | MinutesOfCommitteesInd |
| Officer Mailing Address | false | OfficerMailingAddressInd |
| Local Chapters | Yes (true) | LocalChaptersInd |
| Policies Reference Chapters | Yes (true) | PoliciesReferenceChaptersInd |
| Form990 Provided To Gvrn Body | Yes (true) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (true) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (true) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (true) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (true) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (true) | DocumentRetentionPolicyInd |
| Compensation Process CEO | false | CompensationProcessCEOInd |
| Compensation Process Other | false | CompensationProcessOtherInd |
| Investment In Joint Venture | false | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | AK | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AZ | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CO | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | DE | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | DC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | FL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | GA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | HI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | ID | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | IL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | IN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | LA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MD | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | ME | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MO | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NJ | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NM | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NE | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OK | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | PA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | PR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | RI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | SC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | TN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | UT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | VA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WV | StatesWhereCopyOfReturnIsFldCd |
| Own Website | Yes (X) | OwnWebsiteInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | ROSEMARIE LOFFREDO | PersonNm |
| Phone | 9149495213 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1311 MAMARONECK AVENUE | AddressLine1Txt |
| City | WHITE PLAINS | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 10605 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (41 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt | OfficerOfficerInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd | Former Ofcr Director TrusteeFormerOfcrDirectorTrusteeInd | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd |
|---|---|---|---|---|---|---|---|---|---|---|
| LOUIS J DEGENNARO | ||||||||||
| PRESIDENT & | 40.00 | 1.00 | Yes (X) | $457,834 | $0 | $112,974 | ||||
| ROSEMARIE A LOFFREDO | ||||||||||
| EVP-CAO & CF | 40.00 | 1.00 | Yes (X) | $312,192 | $0 | $24,816 | ||||
| GORDON MILLER JR | ||||||||||
| SVP FINANCE | 40.00 | 1.00 | Yes (X) | $220,116 | $0 | $47,340 | ||||
| MARK ROITHMAYR | ||||||||||
| EVP-CHIEF DE | 40.00 | $353,760 | $0 | $50,033 | Yes (X) | |||||
| GEORGE J OMIROS-TERM APR15 | ||||||||||
| EVP-CHIEF CA | 40.00 | $318,316 | $0 | $50,125 | Yes (X) | |||||
| BRIAN ROSEN - TERM FEB15 | ||||||||||
| CHIEF POLICY | 40.00 | $292,610 | $0 | $29,649 | Yes (X) | |||||
| LEE M GREENBERGER | ||||||||||
| SVP & CHIEF | 40.00 | $284,166 | $0 | $42,905 | Yes (X) | |||||
| JEFFREY COMO-TERM DEC14 | ||||||||||
| CHIEF INFORM | 40.00 | $438,470 | $0 | $21,907 | Yes (X) | |||||
| LISA STOCKMON - TERM SEPT14 | ||||||||||
| EVP-CHIEF MA | 40.00 | $278,930 | $0 | $21,359 | Yes (X) | |||||
| GABRIELLE URQUHART-TERM JUN15 | ||||||||||
| REGIONAL VP | 40.00 | $237,376 | $0 | $19,947 | Yes (X) | |||||
| JOHN E WALTER - TERM FEB14 | ||||||||||
| FORMER PRES | 40.00 | 1.00 | $839,890 | $0 | $24,354 | Yes (X) | ||||
| JAMES H DAVIS PHD | ||||||||||
| CHAIR | 6.00 | 2.00 | Yes (X) | $0 | $0 | $0 | Yes (X) | |||
| ELIZABETH J CLARK | ||||||||||
| VICE CHAIR | 4.00 | 2.00 | Yes (X) | $0 | $0 | $0 | Yes (X) | |||
| KENNETH M SCHWARTZ | ||||||||||
| SECRETARY/TR | 4.00 | 2.00 | Yes (X) | $0 | $0 | $0 | Yes (X) | |||
| DONALD PROCTOR | ||||||||||
| AT-LARGE | 4.00 | 2.00 | Yes (X) | $0 | $0 | $0 | Yes (X) | |||
| JAMES A BECK | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| WILLIAM G BEHNKE | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| JORGE L BENITEZ | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| JAMES E BRADNER | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| PETER B BROCK | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| DANA A CALLOW JR | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| SCOTT A CARROLL | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| WILLIAM S DALTON | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| TIMOTHY DURST | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| GRACIELA C ELETA | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| BERNARD H GARIL | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| BETH E HAWLEY | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| FRANCIE HELLER | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| RAANAN HOROWITZ | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| RICHARD M JEANNERET | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| JOSEPH B KELLEY | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| RALPH LAWSON | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| MICHELLE LE BEAU | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| GILLES LEGAULT | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| CONNIE LINDSEY | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| STEVEN T ROSEN | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| FRANK O SMITH | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| KATHRYN C VECELLIO | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| LOUISE G WARNER | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| KEITH S WHITE | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| RODMAN N MYERS | ||||||||||
| LIFE MEMBER- | 1.00 | $0 | $0 | $0 | Yes (X) | |||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $4,033,660 | TotalReportableCompFromOrgAmt |
| Total Other Compensation | $445,409 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 164 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | Yes (true) | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (true) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | false | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd | ServicesServicesDesc | CompensationCompensationAmt |
|---|---|---|---|---|---|
| OLIVER STAFFING INC | |||||
| 350 LEXINGTON AV SUITE 401 | NEW YORK | NY | 10016 | TEMP STAFFING | $5,843,380 |
| MAIL AMERICA COMMUNICATIONS | |||||
| 174 ELKTON FARM RD | FOREST | VA | 24551 | FUNDRAISING SER | $4,304,214 |
| PATIENT ADVOCACY FOUNDATION | |||||
| 421 BUTLER FARM RD | HAMPTON | VA | 23666 | PAT ASSIST PROC | $4,176,617 |
| RESOLUTE MEDIA LLC | |||||
| 137 W 25TH ST | NEW YORK | NY | 10001 | DIGITAL MARKETI | $2,100,611 |
| COMPETITOR GROUP | |||||
| 9477 WAPLES STREET | SAN DIEGO | CA | 92121 | ENDURANCE SPORT | $1,418,995 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 84 | CntrctRcvdGreaterThan100KCnt |
| Federated Campaigns | $1,859,098 | FederatedCampaignsAmt |
| Fundraising | $162,196,401 | FundraisingAmt |
| All Other Contributions | $119,854,485 | AllOtherContributionsAmt |
| Noncash Contributions | $969,388 | NoncashContributionsAmt |
| Total Contributions | $283,909,984 | TotalContributionsAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $1,877,457 | TotalRevenueColumnAmt |
| Exclusion | $1,877,457 | ExclusionAmt |
Royalties Revenue RoyaltiesRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $13,955 | TotalRevenueColumnAmt |
| Exclusion | $13,955 | ExclusionAmt |
Gross Amount Sales Assets GrossAmountSalesAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $85,663,036 | SecuritiesAmt |
Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $82,627,172 | SecuritiesAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $3,035,864 | SecuritiesAmt |
Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $3,035,864 | TotalRevenueColumnAmt |
| Exclusion | $3,035,864 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Fundraising Gross Income | $15,797,770 | FundraisingGrossIncomeAmt |
| Contri Rpt Fundraising Event | $162,196,401 | ContriRptFundraisingEventAmt |
| Fundraising Direct Expenses | $23,557,444 | FundraisingDirectExpensesAmt |
Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | -$7,759,674 | TotalRevenueColumnAmt |
| Exclusion | -$7,759,674 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gaming Gross Income | $631,918 | GamingGrossIncomeAmt |
| Gaming Direct Expenses | $137,403 | GamingDirectExpensesAmt |
Net Income From Gaming NetIncomeFromGamingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $494,515 | TotalRevenueColumnAmt |
| Exclusion | $494,515 | ExclusionAmt |
Other Revenue Misc OtherRevenueMiscGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | OTHER MISCELLANEOUS | Desc |
| Business | 900099 | BusinessCd |
| Total Revenue Column | $56,829 | TotalRevenueColumnAmt |
| Exclusion | $56,829 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Revenue Total | $56,829 | OtherRevenueTotalAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $281,628,930 | TotalRevenueColumnAmt |
| Exclusion | -$2,281,054 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $58,051,232 | TotalAmt |
| Program Services | $58,051,232 | ProgramServicesAmt |
Grants To Domestic Individuals GrantsToDomesticIndividualsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $42,235,261 | TotalAmt |
| Program Services | $42,235,261 | ProgramServicesAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $7,709,561 | TotalAmt |
| Program Services | $7,709,561 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,904,623 | TotalAmt |
| Program Services | $1,250,249 | ProgramServicesAmt |
| Management And General | $321,172 | ManagementAndGeneralAmt |
| Fundraising | $333,202 | FundraisingAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $68,051,957 | TotalAmt |
| Program Services | $44,648,621 | ProgramServicesAmt |
| Management And General | $11,495,171 | ManagementAndGeneralAmt |
| Fundraising | $11,908,165 | FundraisingAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,663,579 | TotalAmt |
| Program Services | $944,099 | ProgramServicesAmt |
| Management And General | $409,403 | ManagementAndGeneralAmt |
| Fundraising | $310,077 | FundraisingAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $9,358,662 | TotalAmt |
| Program Services | $5,311,142 | ProgramServicesAmt |
| Management And General | $2,303,141 | ManagementAndGeneralAmt |
| Fundraising | $1,744,379 | FundraisingAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $4,700,672 | TotalAmt |
| Program Services | $2,667,682 | ProgramServicesAmt |
| Management And General | $1,156,823 | ManagementAndGeneralAmt |
| Fundraising | $876,167 | FundraisingAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $784,221 | TotalAmt |
| Program Services | $491,513 | ProgramServicesAmt |
| Management And General | $128,390 | ManagementAndGeneralAmt |
| Fundraising | $164,318 | FundraisingAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $292,025 | TotalAmt |
| Program Services | $183,027 | ProgramServicesAmt |
| Management And General | $47,810 | ManagementAndGeneralAmt |
| Fundraising | $61,188 | FundraisingAmt |
Fees For Services Lobbying FeesForServicesLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $623,467 | TotalAmt |
| Program Services | $390,759 | ProgramServicesAmt |
| Management And General | $102,073 | ManagementAndGeneralAmt |
| Fundraising | $130,635 | FundraisingAmt |
Fees For Services Prof Fundraising FeesForServicesProfFundraising
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $4,709,809 | TotalAmt |
| Fundraising | $4,709,809 | FundraisingAmt |
Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $75,197 | TotalAmt |
| Program Services | $47,131 | ProgramServicesAmt |
| Management And General | $12,311 | ManagementAndGeneralAmt |
| Fundraising | $15,755 | FundraisingAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $18,219,202 | TotalAmt |
| Program Services | $11,418,920 | ProgramServicesAmt |
| Management And General | $2,982,803 | ManagementAndGeneralAmt |
| Fundraising | $3,817,479 | FundraisingAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $7,475,264 | TotalAmt |
| Program Services | $3,318,576 | ProgramServicesAmt |
| Management And General | $1,018,944 | ManagementAndGeneralAmt |
| Fundraising | $3,137,744 | FundraisingAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $20,158,375 | TotalAmt |
| Program Services | $8,691,467 | ProgramServicesAmt |
| Management And General | $2,271,929 | ManagementAndGeneralAmt |
| Fundraising | $9,194,979 | FundraisingAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $6,188,376 | TotalAmt |
| Program Services | $3,878,576 | ProgramServicesAmt |
| Management And General | $1,013,146 | ManagementAndGeneralAmt |
| Fundraising | $1,296,654 | FundraisingAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $9,023,616 | TotalAmt |
| Program Services | $5,601,465 | ProgramServicesAmt |
| Management And General | $1,754,904 | ManagementAndGeneralAmt |
| Fundraising | $1,667,247 | FundraisingAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $5,121,398 | TotalAmt |
| Program Services | $3,449,430 | ProgramServicesAmt |
| Management And General | $737,063 | ManagementAndGeneralAmt |
| Fundraising | $934,905 | FundraisingAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,462,185 | TotalAmt |
| Program Services | $1,981,473 | ProgramServicesAmt |
| Management And General | $263,068 | ManagementAndGeneralAmt |
| Fundraising | $217,644 | FundraisingAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $5,721,945 | TotalAmt |
| Program Services | $2,068,849 | ProgramServicesAmt |
| Management And General | $2,473,456 | ManagementAndGeneralAmt |
| Fundraising | $1,179,640 | FundraisingAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $594,312 | TotalAmt |
| Program Services | $247,009 | ProgramServicesAmt |
| Management And General | $236,700 | ManagementAndGeneralAmt |
| Fundraising | $110,603 | FundraisingAmt |
Other Expenses OtherExpensesGrp (2 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt | FundraisingFundraisingAmt |
|---|---|---|---|---|
| MISCELLANEOUS | $2,027,268 | $1,079,451 | $466,829 | $480,988 |
| DUES & SUBSCRIPTIONS | $290,850 | $129,120 | $39,645 | $122,085 |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $277,443,057 | TotalAmt |
| Program Services | $205,794,613 | ProgramServicesAmt |
| Management And General | $29,234,781 | ManagementAndGeneralAmt |
| Fundraising | $42,413,663 | FundraisingAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Joint Costs | Yes (X) | JointCostsInd |
Total Joint Costs TotalJointCostsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $12,521,693 | TotalAmt |
| Program Services | $2,812,241 | ProgramServicesAmt |
| Fundraising | $9,709,452 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $6,268,949 | BOYAmt |
| EOY | $7,141,619 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $20,220,498 | BOYAmt |
| EOY | $42,601,449 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $8,575,572 | BOYAmt |
| EOY | $8,633,988 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $311 | BOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $4,955,078 | BOYAmt |
| EOY | $5,813,918 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $35,132,960 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $20,430,449 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $16,409,608 | BOYAmt |
| EOY | $14,702,511 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $128,829,280 | BOYAmt |
| EOY | $86,639,070 | EOYAmt |
Investments Other Securities InvestmentsOtherSecuritiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $57,322,231 | BOYAmt |
| EOY | $48,953,251 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $242,581,527 | BOYAmt |
| EOY | $214,485,806 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $20,275,231 | BOYAmt |
| EOY | $17,799,196 | EOYAmt |
Grants Payable GrantsPayableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $99,130,986 | BOYAmt |
| EOY | $81,859,872 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $26,038,202 | BOYAmt |
| EOY | $17,304,792 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $145,444,419 | BOYAmt |
| EOY | $116,963,860 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows SFAS117 | Yes (X) | OrganizationFollowsSFAS117Ind |
Unrestricted Net Assets UnrestrictedNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $67,582,758 | BOYAmt |
| EOY | $71,640,456 | EOYAmt |
Temporarily Rstr Net Assets TemporarilyRstrNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $26,592,408 | BOYAmt |
| EOY | $22,847,577 | EOYAmt |
Permanently Rstr Net Assets PermanentlyRstrNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,961,942 | BOYAmt |
| EOY | $3,033,913 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $97,137,108 | BOYAmt |
| EOY | $97,521,946 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $242,581,527 | BOYAmt |
| EOY | $214,485,806 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part XI | Yes (X) | InfoInScheduleOPartXIInd |
| Reconcilation Revenue Expnss | $4,185,873 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | -$3,934,019 | NetUnrlzdGainsLossesInvstAmt |
| Other Changes In Net Assets | $132,984 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | Yes (true) | AccountantCompileOrReviewInd |
| FS Audited | Yes (true) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Consolidated Basis Fincl Stmt | Yes (X) | ConsolidatedBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (true) | AuditCommitteeInd |
| Federal Grant Audit Required | false | FederalGrantAuditRequiredInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $270,043,865 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $282,672,072 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $279,789,664 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $302,437,152 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $283,909,984 | CurrentTaxYearAmt |
| Total | $1,418,852,737 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $270,043,865 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $282,672,072 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $279,789,664 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $302,437,152 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $283,909,984 | CurrentTaxYearAmt |
| Total | $1,418,852,737 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $222,588,669 | SubstantialContributorsTotAmt |
| Public Support Total170 | $1,196,264,068 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $3,145,637 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $2,705,046 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $2,260,636 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $1,203,865 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $1,891,412 | CurrentTaxYearAmt |
| Total | $11,206,596 | TotalAmt |
Other Income170 OtherIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $1,779,485 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $1,502,044 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $1,974,227 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $104,879 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $56,829 | CurrentTaxYearAmt |
| Total | $5,417,464 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $1,435,476,797 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $160,341,605 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.83340 | PublicSupportCY170Pct |
| Public Support PY170 | 0.84500 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Form990 Schedule A Part VI Form990ScheduleAPartVIGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART II, LINE 10 | FormAndLineReferenceDesc |
| Explanation | GRANT TERMINATIONS & REFUNDS 5,069,350 OTHER MISC. REVENUE 348,114 | ExplanationTxt |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule C IRS990ScheduleC
| Field | Value | IRS element (for citing) |
|---|---|---|
| Volunteers | Yes (true) | VolunteersInd |
| Paid Staff Or Management | Yes (true) | PaidStaffOrManagementInd |
| Media Advertisements | false | MediaAdvertisementsInd |
| Mailings Members | false | MailingsMembersInd |
| Publications Or Broadcast | Yes (true) | PublicationsOrBroadcastInd |
| Publications Or Broadcast | $149,762 | PublicationsOrBroadcastAmt |
| Grants Other Organizations | false | GrantsOtherOrganizationsInd |
| Direct Contact Legislators | Yes (true) | DirectContactLegislatorsInd |
| Direct Contact Legislators | $164,749 | DirectContactLegislatorsAmt |
| Rallies Demonstrations | Yes (true) | RalliesDemonstrationsInd |
| Rallies Demonstrations | $236,088 | RalliesDemonstrationsAmt |
| Other Activities | Yes (true) | OtherActivitiesInd |
| Other Activities | $623,467 | OtherActivitiesAmt |
| Total Lobbying Expenditures | $1,174,066 | TotalLobbyingExpendituresAmt |
| Not Described Section501c3 | false | NotDescribedSection501c3Ind |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | SCHEDULE C, PART II-B, LINE 1 | FormAndLineReferenceDesc |
| Explanation | LLS IS A MEMBER OF A NUMBER OF COALITIONS AND MEMBERSHIPS INCLUDING FRIENDS OF CANCER RESEARCH, ALLIANCE FOR A STRONGER FDA, ONE VOICE AGAINST CANCER, NATIONAL HEALTH COUNCIL, THE CANCER LEADERSHIP COUNCIL AND THE STATE ACCESS TO INNOVATIVE MEDICINES COALITION. LLS PARTNERS WITH A NUMBER OF LOBBYING FIRMS WHO WORK WITH OUR PUBLIC POLICY STAFF TO CARRY OUT OUR LOBBYING OBJECTIVES. LLS MOBILIZES PATIENT-ADVOCATES AND VOLUNTEERS TO ENGAGE WITH THEIR FEDERAL AND STATE LEGISLATORS THROUGH DIGITAL ADVOCACY - SENDING LETTERS; SHARING THEIR PERSONAL STORIES; SIGNING PETITIONS; AND ENCOURAGING THEIR LEGISLATORS TO SUPPORT LLS' POLICY PRIORITIES. IN CONJUNCTION WITH LLS EMPLOYEES, PATIENT-ADVOCATES ALSO VISIT THEIR LEGISLATORS IN THEIR LOCAL OFFICES, IN WASHINGTON, DC AND IN STATE CAPITOLS TO FURTHER LLS' POLICY AGENDA. | ExplanationTxt |
Schedule D IRS990ScheduleD
| Field | Value | IRS element (for citing) |
|---|---|---|
| Collection Used Pub Exhibition | Yes (X) | CollectionUsedPubExhibitionInd |
| Solicited Assets Sale | false | SolicitedAssetsSaleInd |
CY Endwmt Fund CYEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $6,122,698 | BeginningYearBalanceAmt |
| Investment Earnings Or Losses | $218,549 | InvestmentEarningsOrLossesAmt |
| Grants Or Scholarships | -$221,499 | GrantsOrScholarshipsAmt |
| Administrative Expenses | -$4,103 | AdministrativeExpensesAmt |
| End Year Balance | $6,115,645 | EndYearBalanceAmt |
CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $6,027,657 | BeginningYearBalanceAmt |
| Investment Earnings Or Losses | $313,872 | InvestmentEarningsOrLossesAmt |
| Grants Or Scholarships | -$215,000 | GrantsOrScholarshipsAmt |
| Administrative Expenses | -$3,831 | AdministrativeExpensesAmt |
| End Year Balance | $6,122,698 | EndYearBalanceAmt |
CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $6,000,186 | BeginningYearBalanceAmt |
| Investment Earnings Or Losses | $482,520 | InvestmentEarningsOrLossesAmt |
| Grants Or Scholarships | -$450,000 | GrantsOrScholarshipsAmt |
| Administrative Expenses | -$5,049 | AdministrativeExpensesAmt |
| End Year Balance | $6,027,657 | EndYearBalanceAmt |
CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $6,059,994 | BeginningYearBalanceAmt |
| Investment Earnings Or Losses | $48,916 | InvestmentEarningsOrLossesAmt |
| Administrative Expenses | -$9,992 | AdministrativeExpensesAmt |
| End Year Balance | $6,000,186 | EndYearBalanceAmt |
CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $5,023,902 | BeginningYearBalanceAmt |
| Contributions | $111,064 | ContributionsAmt |
| Investment Earnings Or Losses | $938,068 | InvestmentEarningsOrLossesAmt |
| Administrative Expenses | -$13,040 | AdministrativeExpensesAmt |
| End Year Balance | $6,059,994 | EndYearBalanceAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Prmnnt Endowment Balance EOY | 0.50000 | PrmnntEndowmentBalanceEOYPct |
| Term Endowment Balance EOY | 0.50000 | TermEndowmentBalanceEOYPct |
| Endowments Held Unrelated Org | false | EndowmentsHeldUnrelatedOrgInd |
| Endowments Held Related Org | false | EndowmentsHeldRelatedOrgInd |
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $942,329 | OtherCostOrOtherBasisAmt |
| Depreciation | $504,716 | DepreciationAmt |
| Book Value | $437,613 | BookValueAmt |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $31,500,031 | OtherCostOrOtherBasisAmt |
| Depreciation | $17,235,878 | DepreciationAmt |
| Book Value | $14,264,153 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $2,690,600 | OtherCostOrOtherBasisAmt |
| Depreciation | $2,689,855 | DepreciationAmt |
| Book Value | $745 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $14,702,511 | TotalBookValueLandBuildingsAmt |
Other Securities OtherSecuritiesGrp (3 entries)
| DescDesc | Book ValueBookValueAmt | Method ValuationMethodValuationCd |
|---|---|---|
| FUND OF HEDGE FUNDS- OPERATING | $46,036,786 | F |
| 457B PLAN | $1,491,954 | F |
| FUND OF HEDGE FUNDS-ENDOWMENT | $1,424,511 | F |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Securities | $48,953,251 | TotalBookValueSecuritiesAmt |
| Footnote Text | Yes (X) | FootnoteTextInd |
| Total Rev Etc Audited Fincl Stmt | $298,163,084 | TotalRevEtcAuditedFinclStmtAmt |
| Net Unrealized Gains Invst | -$3,934,019 | NetUnrealizedGainsInvstAmt |
| Donated Services And Use Fclts | $9,864,376 | DonatedServicesAndUseFcltsAmt |
| Other Revenue | $10,678,994 | OtherRevenueAmt |
| Revenue Not Reported | $16,609,351 | RevenueNotReportedAmt |
| Revenue Subtotal | $281,553,733 | RevenueSubtotalAmt |
| Investment Expenses Not Incld | $75,197 | InvestmentExpensesNotIncldAmt |
| Revenue Not Reported Fincl Stmt | $75,197 | RevenueNotReportedFinclStmtAmt |
| Total Revenue Per Form990 | $281,628,930 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $297,885,296 | TotExpnsEtcAuditedFinclStmtAmt |
| Donated Services Use Fclts | $9,864,376 | DonatedServicesUseFcltsAmt |
| Other Expenses Included | $10,653,060 | OtherExpensesIncludedAmt |
| Expenses Not Reported | $20,517,436 | ExpensesNotReportedAmt |
| Expenses Subtotal | $277,367,860 | ExpensesSubtotalAmt |
| Investment Expenses Not Incld2 | $75,197 | InvestmentExpensesNotIncld2Amt |
| Expenses Not Rpt Fincl Stmt | $75,197 | ExpensesNotRptFinclStmtAmt |
| Total Expenses Per Form990 | $277,443,057 | TotalExpensesPerForm990Amt |
Supplemental Information Detail SupplementalInformationDetail (5 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| SCHEDULE D, PAGE 2, PART III, LINE 4 | THE LLS COLLECTION IS OF PHOTOGRAPHS WHICH ARE USED FOR PUBLIC EXHIBITION AT FUNDRAISING EVENTS HELD TO SUPPORT LLS'S PROGRAMS. |
| SCHEDULE D, PAGE 2, PART V, LINE 4 | LLS'S ENDOWMENTS ARE INTENDED TO FUND RESEARCH AS WELL AS SUPPORT LLS'S PUBLIC EDUCATION PROGRAMS. |
| SCHEDULE D, PAGE 3, PART X | LLS RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE TAX POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO LLS'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENUE CODE SECTION 511. LLS DID NOT RECOGNIZE ANY UNRELATED BUSINESS INCOME TAX LIABILITY FOR THE YEARS ENDED JUNE 30, 2015 AND 2014. |
| SCHEDULE D, PAGE 4, PART XI, LINE 2D | LLS CANADA REVENUE 10,501,177 LLS CANADA GAIN ON INVESTMENT 177,817 |
| SCHEDULE D, PAGE 4, PART XII, LINE 2D | LLS CANADA EXPENSES 10,122,744 FOREIGN CURRENCY TRANSLATION 530,316 |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (true) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (4 entries)
| RegionRegionTxt | EmployeeEmployeeCnt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Specific Services ProvidedSpecificServicesProvidedTxt | Region Total ExpendituresRegionTotalExpendituresAmt | OfficesOfficesCnt |
|---|---|---|---|---|---|
| EAST ASIA | 3 | RESEARCH FUNDING | RESEARCH GRANTS | $1,695,000 | |
| EUROPE | 13 | RESEARCH FUNDING | RESEARCH GRANTS | $4,351,803 | |
| NORTH AMERICA | 6 | RESEARCH FUNDING | RESEARCH GRANTS | $1,662,758 | 7 |
| CENTRAL AMERICA & CARIBBEAN | INVESTMENTS | INVESTMENTS | $20,635,431 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 7 | SubtotalOfficesCnt |
| Subtotal Employees | 22 | SubtotalEmployeesCnt |
| Total Office | 7 | TotalOfficeCnt |
| Total Employee | 22 | TotalEmployeeCnt |
| Subtotal Spent | $28,344,992 | SubtotalSpentAmt |
| Total Spent | $28,344,992 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp (22 entries)
| RegionRegionTxt | Purpose Of GrantPurposeOfGrantTxt | Cash GrantCashGrantAmt | Manner Of Cash DisbursementMannerOfCashDisbursementTxt | Valuation Method UsedValuationMethodUsedDesc |
|---|---|---|---|---|
| EAST ASIA & PACIFIC | RESEARCH GRANT | $1,250,000 | CHECK | ACCRUAL |
| EAST ASIA & PACIFIC | RESEARCH GRANT | $55,000 | CHECK | ACCRUAL |
| EAST ASIA & PACIFIC | RESEARCH GRANT | $390,000 | CHECK | ACCRUAL |
| EUROPE | RESEARCH GRANT | $65,000 | CHECK | ACCRUAL |
| EUROPE | RESEARCH GRANT | $200,000 | CHECK | ACCRUAL |
| EUROPE | RESEARCH GRANT | $55,000 | CHECK | ACCRUAL |
| EUROPE | RESEARCH GRANT | $1,250,000 | CHECK | ACCRUAL |
| EUROPE | RESEARCH GRANT | $110,000 | CHECK | ACCRUAL |
| EUROPE | RESEARCH GRANT | $200,000 | CHECK | ACCRUAL |
| EUROPE | RESEARCH GRANT | $200,000 | CHECK | ACCRUAL |
| EUROPE | RESEARCH GRANT | $395,665 | CHECK | ACCRUAL |
| EUROPE | THERAPY ACCELERATION | $1,000,000 | WIRE | FMV |
| EUROPE | THERAPY ACCELERATION | $750,000 | WIRE | FMV |
| EUROPE | THERAPY ACCELERATION | $16,138 | CHECK | FMV |
| EUROPE | THERAPY ACCELERATION | $10,000 | CHECK | FMV |
| EUROPE | THERAPY ACCELERATION | $100,000 | CHECK | FMV |
| NORTH AMERICA | RESEARCH GRANT | $200,000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | $200,000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | $300,000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | $200,000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | $363,353 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | $399,405 | CHECK | ACCRUAL |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Org | 18 | TotalOtherOrgCnt |
| Transfer To Foreign Corp | Yes (true) | TransferToForeignCorpInd |
| Interest In Foreign Trust | false | InterestInForeignTrustInd |
| Foreign Corp Ownership | Yes (true) | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | Yes (true) | PassiveForeignInvestmestCoInd |
| Foreign Partnership | false | ForeignPartnershipInd |
| Boycott Countries | false | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| SCHEDULE F, PAGE 1, PART I, LINE 2 | FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. |
| SCHEDULE F, PAGE 1, PART I, LINE 3 | EAST ASIA 1,695,000 0 EUROPE 4,351,803 0 NORTH AMERICA 1,662,758 0 CENTRAL AMERICA & CARIBBEAN 0 20,635,431 |
Schedule G IRS990ScheduleG
| Field | Value | IRS element (for citing) |
|---|---|---|
| Mail Solicitations | Yes (X) | MailSolicitationsInd |
| Email Solicitations | Yes (X) | EmailSolicitationsInd |
| Phone Solicitations | Yes (X) | PhoneSolicitationsInd |
| In Person Solicitations | Yes (X) | InPersonSolicitationsInd |
| Solicitation Of Non Govt Grants | Yes (X) | SolicitationOfNonGovtGrantsInd |
| Special Fundraising Events | Yes (X) | SpecialFundraisingEventsInd |
| Agrmt Prof Fundraising Acty | Yes (true) | AgrmtProfFundraisingActyInd |
Fundraiser Activity Info FundraiserActivityInfoGrp (5 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | ActivityActivityTxt | Fundraiser Control Of FundsFundraiserControlOfFundsInd | Retained By ContractorRetainedByContractorAmt | Net To OrganizationNetToOrganizationAmt |
|---|---|---|---|---|---|---|---|
| MAIL AMERICA COMMUNICATIONS INC | |||||||
| 174 ELKTON FARM ROAD | FOREST | VA | 24551 | DIRECT MAI | false | $5,000,715 | -$5,000,715 |
| INFOCISION MANAGEMENT CORPORATION | |||||||
| 325 SPRINSIDE DRIVE | AKRON | OH | 44333 | TELEMARKET | false | $828,717 | -$828,717 |
| THOMPSON HABIB & DENISON | |||||||
| 80 HAYDEN AVENUE SUITE 300 | LEXINGTON | MA | 02421 | DIRECT MAI | false | $575,275 | -$575,275 |
| COINSTAR | |||||||
| 1800 114TH AVENUE SE | BELLEVUE | WA | 98004 | COIN COLLE | false | $400,303 | -$400,303 |
| DONOR CARE CENTER INC | |||||||
| 4345 STRAUSSSER ST NW | NORTH CANTON | OH | 44720 | TELEMARKET | false | $212,080 | -$212,080 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Retained By Contractors | $7,017,090 | TotalRetainedByContractorsAmt |
| Total Net To Organization | -$7,017,090 | TotalNetToOrganizationAmt |
| All States | All States | AllStatesCd |
Fundraising Event Information FundraisingEventInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Event1 | NIKE WOMEN MARA | Event1Nm |
| Gross Receipts Event1 | $4,507,326 | GrossReceiptsEvent1Amt |
| Charitable Contri Event1 | $4,476,491 | CharitableContriEvent1Amt |
| Gross Revenue Event1 | $30,835 | GrossRevenueEvent1Amt |
| Non Cash Prizes Event1 | $8,829 | NonCashPrizesEvent1Amt |
| Rent Facility Costs Event1 | $556,046 | RentFacilityCostsEvent1Amt |
| Food And Beverage Event1 | $77,427 | FoodAndBeverageEvent1Amt |
| Other Direct Expenses Event1 | $547,023 | OtherDirectExpensesEvent1Amt |
| Event2 | LAKE TAHOE CYCL | Event2Nm |
| Gross Receipts Event2 | $3,308,624 | GrossReceiptsEvent2Amt |
| Charitable Contri Event2 | $3,294,124 | CharitableContriEvent2Amt |
| Gross Revenue Event2 | $14,500 | GrossRevenueEvent2Amt |
| Non Cash Prizes Event2 | $63,659 | NonCashPrizesEvent2Amt |
| Rent Facility Costs Event2 | $190,171 | RentFacilityCostsEvent2Amt |
| Food And Beverage Event2 | $31,311 | FoodAndBeverageEvent2Amt |
| Other Direct Expenses Event2 | $261,890 | OtherDirectExpensesEvent2Amt |
| Other Events Total | 741 | OtherEventsTotalCnt |
| Gross Receipts Other Events | $170,178,221 | GrossReceiptsOtherEventsAmt |
| Charitable Contri Other Events | $154,425,786 | CharitableContriOtherEventsAmt |
| Gross Revenue Other Events | $15,752,435 | GrossRevenueOtherEventsAmt |
| Non Cash Prizes Other Events | $3,806,128 | NonCashPrizesOtherEventsAmt |
| Rent Fclty Costs Other Events | $7,237,129 | RentFcltyCostsOtherEventsAmt |
| Food And Beverage Other Events | $3,240,623 | FoodAndBeverageOtherEventsAmt |
| Entertainment Other Events | $1,083,633 | EntertainmentOtherEventsAmt |
| Oth Direct Expnss Other Events | $6,453,575 | OthDirectExpnssOtherEventsAmt |
| Gross Receipts Total | $177,994,171 | GrossReceiptsTotalAmt |
| Charitable Contributions Tot | $162,196,401 | CharitableContributionsTotAmt |
| Gross Revenue Total Events | $15,797,770 | GrossRevenueTotalEventsAmt |
| Non Cash Prizes Total Events | $3,878,616 | NonCashPrizesTotalEventsAmt |
| Rent Fclty Costs Total Events | $7,983,346 | RentFcltyCostsTotalEventsAmt |
| Food And Beverage Total Events | $3,349,361 | FoodAndBeverageTotalEventsAmt |
| Entertainment Total Events | $1,083,633 | EntertainmentTotalEventsAmt |
| Oth Direct Expnss Total Events | $7,262,488 | OthDirectExpnssTotalEventsAmt |
| Direct Expense Summary Events | $23,557,444 | DirectExpenseSummaryEventsAmt |
| Net Income Summary | -$7,759,674 | NetIncomeSummaryAmt |
Gaming Information GamingInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Volunteer Labor Bingo | false | VolunteerLaborBingoInd |
| Volunteer Labor Pull Tabs | false | VolunteerLaborPullTabsInd |
| Gross Revenue Other Gaming | $631,918 | GrossRevenueOtherGamingAmt |
| Cash Prizes Other Gaming | $3,913 | CashPrizesOtherGamingAmt |
| Non Cash Prizes Other Gaming | $129,490 | NonCashPrizesOtherGamingAmt |
| Oth Direct Expnss Other Gaming | $4,000 | OthDirectExpnssOtherGamingAmt |
| Volunteer Labor Other Gaming | Yes (true) | VolunteerLaborOtherGamingInd |
| Volunteer Labor Other Gaming | 0.90000 | VolunteerLaborOtherGamingPct |
| Gross Revenue Total Gaming | $631,918 | GrossRevenueTotalGamingAmt |
| Cash Prizes Total Gaming | $3,913 | CashPrizesTotalGamingAmt |
| Non Cash Prizes Total Gaming | $129,490 | NonCashPrizesTotalGamingAmt |
| Oth Direct Expnss Total Gaming | $4,000 | OthDirectExpnssTotalGamingAmt |
| Direct Expense Summary Gaming | $137,403 | DirectExpenseSummaryGamingAmt |
| Net Gaming Income Summary | $494,515 | NetGamingIncomeSummaryAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Licensed | Yes (true) | LicensedInd |
| License Suspended Etc | false | LicenseSuspendedEtcInd |
| Gaming With Nonmembers | false | GamingWithNonmembersInd |
| Member Of Other Entity | false | MemberOfOtherEntityInd |
| Gaming Own Facility | 0.25000 | GamingOwnFacilityPct |
| Gaming Other Facility | 0.75000 | GamingOtherFacilityPct |
| Individual With Books | ROSEMARIE LOFFREDO | IndividualWithBooksNm |
Persons With Books US Address PersonsWithBooksUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1311 MAMARONECK AVENUE | AddressLine1Txt |
| City | WHITE PLAINS | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 10605 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct With3rd Prty For Game Rev | false | CntrctWith3rdPrtyForGameRevInd |
| Gaming Manager Person | SEE SCHEDULE G PART IV | GamingManagerPersonNm |
| Charitable Distribution Rqr | false | CharitableDistributionRqrInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | SCHEDULE G, PART IV | FormAndLineReferenceDesc |
| Explanation | SCHEDULE G PART I, LINE 2B LLS USED MAIL AMERICA COMMUNICATIONS AND THOMPSON, HABIB & DENISON FOR ITS NATIONAL COMMUNITY CAMPAIGN AND DIRECT MAIL PROGRAMS. THESE PROGRAMS GENERATED GROSS RECEIPTS OF 20,336,576 DURING FISCAL YEAR 2015. LLS USED INFOCISION MANAGEMENT CORPORATION, COINSTAR AND DONOR CARE CENTER FOR ALL OF ITS OTHER FUNDRAISING EVENTS DURING FISCAL YEAR 2015. SCHEDULE G, PART II - LINE 2 CONTRIBUTIONS REPRESENT THE CASH DONATIONS IN EXCESS OF THE FAIR MARKET VALUE OF BENEFITS PROVIDED TO THE DONOR. SCHEDULE G, PART II, LINES 4 - 10 DIRECT EXPENSES ARE COSTS INCURRED BY THE ORGANIZATION TO HOST THE EVENTS. SCHEDULE G, PART III, LINE 9 - STATES WITH GAMING OPERATIONS ARIZONA, DISTRICT OF COLUMBIA, IOWA, KANSAS, LOUISIANA, MICHIGAN, NEVADA, NEW YORK, OHIO, OREGON, PENNSYLVANIA, RHODE ISLAND, TEXAS, WISCONSIN. SCHEDULE G, PART III, LINE 16 THE LEUKEMIA & LYMPHOMA SOCIETY DOES NOT HAVE AN OVERALL MANAGER FOR GAMING ACTIVITIES. EACH GAMING EVENT IS MANAGED LOCALLY BY THE SPECIFIC CHAPTER STAFF. | ExplanationTxt |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (true) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (282 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Valuation Method UsedValuationMethodUsedDesc | Purpose Of GrantPurposeOfGrantTxt |
|---|---|---|---|---|---|---|---|---|
| ALBERT EINSTEIN COLLEGE OF MEDICINE | ||||||||
| 1300 MORRSIS PARK AVE | BRONX | NY | 10461 | 131624225 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| ALBERT EINSTEIN COLLEGE OF MEDICINE | ||||||||
| 1300 MORRSIS PARK AVE | BRONX | NY | 10461 | 131624225 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| ALBERT EINSTEIN COLLEGE OF MEDICINE | ||||||||
| 1300 MORRSIS PARK AVE | BRONX | NY | 10461 | 131624225 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| ALBERT EINSTEIN COLLEGE OF MEDICINE | ||||||||
| 1300 MORRSIS PARK AVE | BRONX | NY | 10461 | 131624225 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| ALBERT EINSTEIN COLLEGE OF MEDICINE | ||||||||
| 1300 MORRSIS PARK AVE | BRONX | NY | 10461 | 131624225 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| ALBERT EINSTEIN COLLEGE OF MEDICINE | ||||||||
| 1300 MORRSIS PARK AVE | BRONX | NY | 10461 | 131624225 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| BAYLOR COLLEGE OF MEDICINE | ||||||||
| 1 BAYLOR PLAZA | HOUSTON | TX | 77030 | 741613878 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| BAYLOR COLLEGE OF MEDICINE | ||||||||
| 1 BAYLOR PLAZA | HOUSTON | TX | 77031 | 741613878 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| BAYLOR COLLEGE OF MEDICINE | ||||||||
| 1 BAYLOR PLAZA | HOUSTON | TX | 77032 | 741613878 | 3 | $1,250,000 | ACCRUAL | RESEARCH GRANT |
| BAYLOR COLLEGE OF MEDICINE | ||||||||
| 1 BAYLOR PLAZA | HOUSTON | TX | 77033 | 741613878 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| BECKMAN RESEARCH INSTITUTE OF CITY | ||||||||
| 1500 DUARTE ROAD | DUARTE | CA | 910103000 | 953432210 | 3 | $400,000 | ACCRUAL | RESEARCH GRANT |
| BECKMAN RESEARCH INSTITUTE OF THE C | ||||||||
| 1500 DUARTE ROAD | DUARTE | CA | 91010 | 953432210 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| BECKMAN RESEARCH INSTITUTE OF THE C | ||||||||
| 1500 DUARTE ROAD | DUARTE | CA | 91010 | 953432210 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| BETH ISRAEL DEACONESS MEDICAL CENTE | ||||||||
| 330 BROOKLINE AVENUE | BOSTON | MA | 02215 | 042103881 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| BETH ISRAEL DEACONESS MEDICAL CENTE | ||||||||
| 330 BROOKLINE AVENUE | BOSTON | MA | 02215 | 042103881 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| BETH ISRAEL DEACONESS MEDICAL CENTE | ||||||||
| 330 BROOKLINE AVENUE | BOSTON | MA | 02215 | 042103881 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| BRANDEIS UNIVERSITY | ||||||||
| 415 SOUTH STREET | WALTHAM | MA | 02453 | 042103552 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| BRIGHAM & WOMENS HOSPITAL | ||||||||
| 75 FRANCIS STREET | BOSTON | MA | 02115 | 042312909 | 3 | $1,250,000 | ACCRUAL | RESEARCH GRANT |
| BRIGHAM & WOMENS HOSPITAL | ||||||||
| 75 FRANCIS STREET | BOSTON | MA | 02115 | 042312909 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| BRIGHAM & WOMENS HOSPITAL | ||||||||
| 75 FRANCIS STREET | BOSTON | MA | 02115 | 042312909 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| BRIGHAM & WOMENS HOSPITAL | ||||||||
| 75 FRANCIS STREET | BOSTON | MA | 02115 | 042312909 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| BRIGHAM & WOMENS HOSPITAL | ||||||||
| 75 FRANCIS STREET | BOSTON | MA | 02115 | 042312909 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| CALIFORNIA INSTITUTE OF TECHNOLOGY | ||||||||
| 12200 E CALIFORNIA BLVD | PASADENA | CA | 91125 | 951643307 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| CALIFORNIA INSTITUTE OF TECHNOLOGY | ||||||||
| 12200 E CALIFORNIA BLVD | PASADENA | CA | 91125 | 951643307 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| CASE WESTERN RESERVE UNIVERSITY - S | ||||||||
| 2109 ADELBERT ROAD | CLEVELAND | OH | 44106 | 341018992 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| CASE WESTERN RESERVE UNIVERSITY - S | ||||||||
| 2109 ADELBERT ROAD | CLEVELAND | OH | 44106 | 341018992 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| CEDARS-SINAI MEDICAL CENTER | ||||||||
| 8700 BEVERLY BLVD | LOS ANGELES | CA | 90048 | 951644600 | 3 | $133,333 | ACCRUAL | RESEARCH GRANT |
| CHILDRENS HOSPITAL CORPORATION | ||||||||
| 300 LONGWOOD AVENUE | BOSTON | MA | 02115 | 042774441 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| CHILDRENS HOSPITAL CORPORATION | ||||||||
| 300 LONGWOOD AVENUE | BOSTON | MA | 02115 | 042774441 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| CHILDRENS HOSPITAL CORPORATION | ||||||||
| 300 LONGWOOD AVENUE | BOSTON | MA | 02115 | 042774441 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| CHILDRENS HOSPITAL CORPORATION | ||||||||
| 300 LONGWOOD AVENUE | BOSTON | MA | 02115 | 042774441 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| CHILDREN'S HOSPITAL OF PHILADELPHIA | ||||||||
| CIVIC CENTER BLVD | PHILADELPHIA | PA | 19104 | 231352166 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| CHILDREN'S HOSPITAL OF PHILADELPHIA | ||||||||
| CIVIC CENTER BLVD | PHILADELPHIA | PA | 19104 | 231352166 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| CINCINNATI CHILDRENS HOSPITAL MEDI | ||||||||
| 3333 BURNET AVENUE | CINCINATTI | OH | 45209 | 310833936 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| CINCINNATI CHILDREN'S HOSPITAL MEDI | ||||||||
| 3333 BURNET AVENUE | CINCINATTI | OH | 45209 | 310833936 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| CINCINNATI CHILDREN'S HOSPITAL MEDI | ||||||||
| 3333 BURNET AVENUE | CINCINATTI | OH | 45209 | 310833936 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| CLEVELAND CLINIC FOUNDATION | ||||||||
| 9500 EUCLID AVENUE | CLEVELAND | OH | 44195 | 912153073 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| COLD SPRING HARBOR LABORATORY | ||||||||
| 1 BUNGTOWN ROAD | COLD SPRING HARBOR | NY | 11724 | 112013303 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| COLUMBIA UNIVERSITY MEDICAL CENTER | ||||||||
| 630 WEST 168TH STREET BOX 49 | NEW YORK | NY | 10032 | 135598093 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| COLUMBIA UNIVERSITY MEDICAL CENTER | ||||||||
| 630 WEST 168TH STREET BOX 49 | NEW YORK | NY | 10032 | 135598093 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| COLUMBIA UNIVERSITY MEDICAL CENTER | ||||||||
| 630 WEST 168TH STREET BOX 49 | NEW YORK | NY | 10032 | 135598093 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| COLUMBIA UNIVERSITY MEDICAL CENTER | ||||||||
| 630 WEST 168TH STREET BOX 49 | NEW YORK | NY | 10032 | 135598093 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| COLUMBIA UNIVERSITY MEDICAL CENTER | ||||||||
| 630 WEST 168TH STREET BOX 49 | NEW YORK | NY | 10032 | 135598093 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| COLUMBIA UNIVERSITY MEDICAL CENTER | ||||||||
| 630 WEST 168TH STREET BOX 49 | NEW YORK | NY | 10032 | 135598093 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| COLUMBIA UNIVERSITY MEDICAL CENTER | ||||||||
| 630 WEST 168TH STREET BOX 49 | NEW YORK | NY | 10032 | 135598093 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| COLUMBIA UNIVERSITY MEDICAL CENTER | ||||||||
| 630 WEST 168TH STREET BOX 49 | NEW YORK | NY | 10032 | 135598093 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| COLUMBIA UNIVERSITY MEDICAL CENTER | ||||||||
| 630 WEST 168TH STREET BOX 49 | NEW YORK | NY | 10032 | 135598093 | 3 | $400,000 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $1,250,000 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $288,909 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $136,605 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $15,477 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE | BOSTON | MA | 02215 | 042263040 | 3 | $400,000 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $194,425 | FMV | THERAPY ACCELERATION |
| DANA FARBER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $194,425 | FMV | THERAPY ACCELERATION |
| DUKE UNIVERSITY MEDICAL CENTER | ||||||||
| 134 CHAPEL DRIVE | DURHAM | NC | 27708 | 560532129 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| DUKE UNIVERSITY MEDICAL CENTER | ||||||||
| 134 CHAPEL DRIVE | DURHAM | NC | 27708 | 560532129 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| DUKE UNIVERSITY MEDICAL CENTER | ||||||||
| SPONSORED PROGRAMS 324 BLACKWELL S | DURHAM | NC | 27708 | 560532129 | 3 | $398,985 | ACCRUAL | RESEARCH GRANT |
| EMORY UNIVERSITY | ||||||||
| PO BOX 935084 | ALTANTA | GA | 31193 | 580566256 | 3 | $250,000 | FMV | THERAPY ACCELERATION |
| FOX CHASE CANCER CENTER | ||||||||
| 333 COTTMAN AVENUE | PHILADELPHIA | PA | 191112434 | 232003072 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| FRED HUTCHINSON CANCER RESEARCH CEN | ||||||||
| 1100 FAIRVIEW AVENUE NORTH J6-500 | SEATTLE | WA | 981091024 | 237156071 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| FRED HUTCHINSON CANCER RESEARCH CEN | ||||||||
| 1100 FAIRVIEW AVENUE NORTH J6-500 | SEATTLE | WA | 981091024 | 237156071 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| FRED HUTCHINSON CANCER RESEARCH CEN | ||||||||
| 1100 FAIRVIEW AVENUE NORTH J6-500 | SEATTLE | WA | 981091024 | 237156071 | 3 | $133,333 | ACCRUAL | RESEARCH GRANT |
| FRED HUTCHINSON CANCER RESEARCH CEN | ||||||||
| 1100 FAIRVIEW AVENUE NORTH J6-500 | SEATTLE | WA | 981091024 | 237156071 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| FRED HUTCHINSON CANCER RESEARCH CEN | ||||||||
| 1100 FAIRVIEW AVENUE NORTH J6-500 | SEATTLE | WA | 981091024 | 237156071 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| HARVARD UNIVERSITY | ||||||||
| 25 SHATTUCK STREET ROOM 509 | BOSTON | MA | 02115 | 042103580 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| HARVARD UNIVERSITY | ||||||||
| 25 SHATTUCK STREET ROOM 509 | BOSTON | MA | 02115 | 042103580 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| HOSPITAL FOR SPECIAL SURGERY | ||||||||
| 535 E 70TH STREET | NEW YORK | NY | 10021 | 136714749 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| IMMUNE DISEASE INSTITUTE (FKA) THE | ||||||||
| 3 BLACKFAN CIRCLE CLSB 3RD FLOOR | BOSTON | MA | 02115 | 042158520 | 3 | $1,250,000 | ACCRUAL | RESEARCH GRANT |
| INDIANA UNIVERSITY (INDIANAPOLIS) | ||||||||
| 980 INDIANA AVENUE LOCKEFIELD 2232 | INDIANAPOLIS | IN | 462022915 | 356001673 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| INDIANA UNIVERSITY-PURDUE UNIVERSIT | ||||||||
| 980 INDIANA AVENUE LOCKEFIELD 2232 | INDIANAPOLIS | IN | 462022915 | 356001673 | 3 | $133,333 | ACCRUAL | RESEARCH GRANT |
| JOAN & SANFORD I WEILL MEDICAL COL | ||||||||
| 1300 YORK AVENUE BOX 89 | NEW YORK | NY | 100654805 | 131623978 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| JOAN & SANFORD I WEILL MEDICAL COL | ||||||||
| 1300 YORK AVENUE BOX 89 | NEW YORK | NY | 100654805 | 131623978 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| JOAN & SANFORD I WEILL MEDICAL COL | ||||||||
| 1300 YORK AVENUE BOX 89 | NEW YORK | NY | 100654805 | 131623978 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| JOAN & SANFORD I WEILL MEDICAL COL | ||||||||
| 1300 YORK AVENUE BOX 89 | NEW YORK | NY | 100654805 | 131623978 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| JOAN & SANFORD I WEILL MEDICAL COL | ||||||||
| 1300 YORK AVENUE BOX 89 | NEW YORK | NY | 100654805 | 131623978 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| JOHNS HOPKINS UNIVERSITY SCHOOL OF | ||||||||
| JOHNS HOPKINS UNIVERSITY CENTRAL LO | CHICAGO | IL | 60693 | 520595110 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| JOHNS HOPKINS UNIVERSITY SCHOOL OF | ||||||||
| JOHNS HOPKINS UNIVERSITY CENTRAL LO | CHICAGO | IL | 60693 | 520595110 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| JOHNS HOPKINS UNIVERSITY SCHOOL OF | ||||||||
| JOHNS HOPKINS UNIVERSITY CENTRAL LO | CHICAGO | IL | 60693 | 520595110 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| JOHNS HOPKINS UNIVERSITY SCHOOL OF | ||||||||
| JOHNS HOPKINS UNIVERSITY CENTRAL LO | CHICAGO | IL | 60693 | 520595110 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| JOHNS HOPKINS UNIVERSITY SCHOOL OF | ||||||||
| JOHNS HOPKINS UNIVERSITY CENTRAL LO | CHICAGO | IL | 60693 | 520595110 | 3 | $277,750 | ACCRUAL | RESEARCH GRANT |
| LA JOLLA INSTITUTE FOR ALLERGY AND | ||||||||
| 9420 ATHENA CIRCLE | LA JOLLA | CA | 92037 | 330328688 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| MASSACHUSETTS GENERAL HOSPITAL | ||||||||
| 55 FRUIT STREET | BOSTON | MA | 02114 | 041564655 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| MASSACHUSETTS GENERAL HOSPITAL | ||||||||
| 55 FRUIT STREET | BOSTON | MA | 02114 | 041564655 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| MASSACHUSETTS GENERAL HOSPITAL | ||||||||
| 55 FRUIT STREET | BOSTON | MA | 02114 | 041564655 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| MASSACHUSETTS INSTITUTE OF TECHNOLO | ||||||||
| 77 MASSACHUSETTS AVENUE | CAMBRIDGE | MA | 02139 | 042103594 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| MASSCHUSETTS GENERAL HOSPITAL | ||||||||
| 55 FRUIT STREET | BOSTON | MA | 02114 | 041564655 | 3 | $356,484 | ACCRUAL | RESEARCH GRANT |
| MAYO CLINIC ARIZONA | ||||||||
| 13400 EAST SHEA BLVD | SCOTTSDALE | AZ | 85259 | 416011702 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| MAYO CLINIC ARIZONA | ||||||||
| 13400 EAST SHEA BLVD | SCOTTSDALE | AZ | 85259 | 416011702 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| MAYO CLINIC ROCHESTER | ||||||||
| 200 FIRST STREET SW | ROCHESTER | MN | 55905 | 416011702 | 3 | $300,000 | ACCRUAL | RESEARCH GRANT |
| MAYO CLINIC ROCHESTER | ||||||||
| 200 FIRST STREET SW | ROCHESTER | MN | 55905 | 416011702 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| MAYO CLINIC ROCHESTER | ||||||||
| 200 FIRST STREET SW | ROCHESTER | MN | 55905 | 416011702 | 3 | $320,258 | ACCRUAL | RESEARCH GRANT |
| MEMORIAL SLOAN-KETTERING CANCER CEN | ||||||||
| PO BOX 26338 | NEW YORK | NY | 10087 | 131924236 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| MOFFITT CANCER CENTER AND RESEARCH | ||||||||
| 12902 MAGNOLIA DRIVE | TAMPA | FL | 33612 | 593238636 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| MOFFITT CANCER CENTER AND RESEARCH | ||||||||
| 12902 MAGNOLIA DRIVE | TAMPA | FL | 33612 | 593238636 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| MOUNT SINAI SCHOOL OF MEDICINE | ||||||||
| ICAHN SCHOOL OF MEDICINE AT MOUNT S | NEW YORK | NY | 100296574 | 136171197 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| MOUNT SINAI SCHOOL OF MEDICINE | ||||||||
| ICAHN SCHOOL OF MEDICINE AT MOUNT S | NEW YORK | NY | 100296574 | 136171197 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| NEW YORK UNIVERSITY SCHOOL OF MEDIC | ||||||||
| 545 FIRST AVENUE GBH SC1-55 | NEW YORK | NY | 10016 | 135562308 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| NEW YORK UNIVERSITY SCHOOL OF MEDIC | ||||||||
| 545 FIRST AVENUE GBH SC1-55 | NEW YORK | NY | 10016 | 135562308 | 3 | $1,250,000 | ACCRUAL | RESEARCH GRANT |
| NEW YORK UNIVERSITY SCHOOL OF MEDIC | ||||||||
| 545 FIRST AVENUE GBH SC1-55 | NEW YORK | NY | 10016 | 135562308 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| NORTHWESTERN UNIVERSITY | ||||||||
| ASRSP 633 CLARK ROOM G547 | EVANSTON | IL | 60208 | 362167817 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| NORTHWESTERN UNIVERSITY | ||||||||
| ASRSP 633 CLARK ROOM G547 | EVANSTON | IL | 60208 | 362167817 | 3 | $300,000 | ACCRUAL | RESEARCH GRANT |
| NORTHWESTERN UNIVERSITY | ||||||||
| ASRSP 633 CLARK ROOM G547 | EVANSTON | IL | 60208 | 362167817 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| NORTHWESTERN UNIVERSITY | ||||||||
| ASRSP 633 CLARK ROOM G547 | EVANSTON | IL | 60208 | 362167817 | 3 | $1,250,000 | ACCRUAL | RESEARCH GRANT |
| NORTHWESTERN UNIVERSITY | ||||||||
| ASRSP 633 CLARK ROOM G547 | EVANSTON | IL | 60208 | 362167817 | 3 | $133,333 | ACCRUAL | RESEARCH GRANT |
| OHIO STATE UNIVERSITY | ||||||||
| 1960 KENNY ROAD | COLUMBUS | OH | 43210 | 316025986 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| OHIO STATE UNIVERSITY | ||||||||
| 1960 KENNY ROAD | COLUMBUS | OH | 43210 | 316025986 | 3 | $300,000 | ACCRUAL | RESEARCH GRANT |
| OHIO STATE UNIVERSITY | ||||||||
| 1960 KENNY ROAD | COLUMBUS | OH | 43210 | 316025986 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| OHIO STATE UNIVERSITY | ||||||||
| 1960 KENNY ROAD | COLUMBUS | OH | 43210 | 316025986 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| OREGON HEALTH & SCIENCE UNIVER | ||||||||
| 0690 SW BANCROFT ST | PORTLAND | OR | 97239 | 931176109 | 3 | $1,111,000 | FMV | THERAPY ACCELERATION |
| OREGON HEALTH & SCIENCE UNIVER | ||||||||
| 0690 SW BANCROFT ST | PORTLAND | OR | 97239 | 931176109 | 3 | $555,500 | FMV | THERAPY ACCELERATION |
| OREGON HEALTH & SCIENCE UNIVERSITY | ||||||||
| 3181 SW SAM JACKSON PARK ROAD MAIL | PORTLAND | OR | 97239 | 931176109 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| PRESIDENT & FELLOWS OF HARVARD COLL | ||||||||
| 6TH FLOOR HOLYOKE CENTER 1350 MAS | CAMBRIDGE | MA | 02138 | 042103580 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| PRESIDENT & FELLOWS OF HARVARD COLL | ||||||||
| 6TH FLOOR HOLYOKE CENTER 1350 MAS | CAMBRIDGE | MA | 02138 | 042103580 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| PRESIDENT & FELLOWS OF HARVARD COLL | ||||||||
| 6TH FLOOR HOLYOKE CENTER 1350 MAS | CAMBRIDGE | MA | 02138 | 042103580 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| REGENTS OF THE UNIV OF MICHIGAN | ||||||||
| BOX 223131 | PITTSBURGH | PA | 15251 | 386006309 | 3 | $157,433 | FMV | THERAPY ACCELERATION |
| REGENTS OF THE UNIV OF MICHIGAN | ||||||||
| BOX 223131 | PITTSBURGH | PA | 15251 | 386006309 | 3 | $292,835 | FMV | THERAPY ACCELERATION |
| REGENTS OF THE UNIV OF MICHIGAN | ||||||||
| BOX 223131 | PITTSBURGH | PA | 15251 | 386006309 | 3 | $238,915 | FMV | THERAPY ACCELERATION |
| REGENTS OF THE UNIVERSITY OF MINNES | ||||||||
| 450 MCNAMARA ALUMNI CENTER 200 OAK | MINNEAPOLIS | MN | 55455 | 416007513 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| RHODE ISLAND HOSPITAL | ||||||||
| 593 EDDY STREET ALDRICH 3-317 | PROVIDENCE | RI | 02903 | 050258954 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| ROCKEFELLER UNIVERSITY | ||||||||
| 1230 YORK AVENUE | NEW YORK | NY | 10021 | 131624158 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| ROCKEFELLER UNIVERSITY | ||||||||
| 1230 YORK AVENUE | NEW YORK | NY | 10021 | 131624158 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| SLOAN-KETTERING INSTITUTE FOR CANCE | ||||||||
| PO BOX 26338 | NEW YORK | NY | 10087 | 131924236 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| SLOAN-KETTERING INSTITUTE FOR CANCE | ||||||||
| PO BOX 26338 | NEW YORK | NY | 10087 | 131924236 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| SLOAN-KETTERING INSTITUTE FOR CANCE | ||||||||
| PO BOX 26338 | NEW YORK | NY | 10087 | 131924236 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| SLOAN-KETTERING INSTITUTE FOR CANCE | ||||||||
| PO BOX 26338 | NEW YORK | NY | 10087 | 131924236 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| SLOAN-KETTERING INSTITUTE FOR CANCE | ||||||||
| PO BOX 26338 | NEW YORK | NY | 10087 | 131924236 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| SLOAN-KETTERING INSTITUTE FOR CANCE | ||||||||
| PO BOX 26338 | NEW YORK | NY | 10087 | 131924236 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| SLOAN-KETTERING INSTITUTE FOR CANCE | ||||||||
| PO BOX 26338 | NEW YORK | NY | 10087 | 131924236 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| SLOAN-KETTERING INSTITUTE FOR CANCE | ||||||||
| PO BOX 26338 | NEW YORK | NY | 10087 | 131924236 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| SLOAN-KETTERING INSTITUTE FOR CANCE | ||||||||
| PO BOX 26338 | NEW YORK | NY | 10087 | 131924236 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| SLOAN-KETTERING INSTITUTE FOR CANCE | ||||||||
| PO BOX 26338 | NEW YORK | NY | 10087 | 131924236 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| SLOAN-KETTERING INSTITUTE FOR CANCE | ||||||||
| PO BOX 26338 | NEW YORK | NY | 10087 | 131924236 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| SLOAN-KETTERING INSTITUTE FOR CANCE | ||||||||
| PO BOX 26338 | NEW YORK | NY | 10087 | 131924236 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| SLOAN-KETTERING INSTITUTE FOR CANCE | ||||||||
| PO BOX 26338 | NEW YORK | NY | 10087 | 131924236 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| SLOAN-KETTERING INSTITUTE FOR CANCE | ||||||||
| PO BOX 26338 | NEW YORK | NY | 10087 | 131924236 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| ST JUDE CHILDREN'S RESEARCH HOSPIT | ||||||||
| 332 N LAUDERFDALE | MEMPHIS | TN | 38105 | 620646012 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| STANFORD UNIVERSITY | ||||||||
| PO BOX 44253 | SAN FRANCISCO | CA | 94144 | 941156365 | 3 | $108,692 | FMV | THERAPY ACCELERATION |
| STANFORD UNIVERSITY | ||||||||
| PO BOX 44253 | SAN FRANCISCO | CA | 94144 | 941156365 | 3 | $333,000 | FMV | THERAPY ACCELERATION |
| STOWERS INSTITUTE FOR MEDICAL RESEA | ||||||||
| 1000 EAST 50TH STREET | KANSAS CITY | MO | 64110 | 202993509 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| SUNY UPSTATE MEDICAL UNIVERSITY | ||||||||
| 4283 WEISKOTTEN HALL 750 EAST ADAM | SYRACUSE | NY | 13210 | 166038703 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| TEMPLE UNIVERSITY | ||||||||
| 3307 NORTH BROAD STREET | PHILADELPHIA | PA | 19140 | 231365971 | 3 | $400,000 | ACCRUAL | RESEARCH GRANT |
| THE BOARD OF REGENTS OF THE UNIVERS | ||||||||
| 21 N PARK ST SUITE 6401 | MADISON | WI | 537151218 | 396006492 | 3 | $215,000 | ACCRUAL | RESEARCH GRANT |
| THE BOARD OF REGENTS OF THE UNIVERS | ||||||||
| 21 N PARK ST SUITE 6401 | MADISON | WI | 537151218 | 396006492 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE BOARD OF TRUSTEES OF THE LELAND | ||||||||
| 3160 PORTER DRIVE SUITE 100 | PALO ALTO | CA | 94304 | 941156365 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE BOARD OF TRUSTEES OF THE LELAND | ||||||||
| 3160 PORTER DRIVE SUITE 100 | PALO ALTO | CA | 94304 | 941156365 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| THE BOARD OF TRUSTEES OF THE LELAND | ||||||||
| 3160 PORTER DRIVE SUITE 100 | PALO ALTO | CA | 94304 | 941156365 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| THE BOARD OF TRUSTEES OF THE LELAND | ||||||||
| 3160 PORTER DRIVE SUITE 100 | PALO ALTO | CA | 94304 | 941156365 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| THE BOARD OF TRUSTEES OF THE LELAND | ||||||||
| 3160 PORTER DRIVE SUITE 100 | PALO ALTO | CA | 94304 | 941156365 | 3 | $268,353 | ACCRUAL | RESEARCH GRANT |
| THE BOARD OF TRUSTEES OF THE LELAND | ||||||||
| 3160 PORTER DRIVE SUITE 100 | PALO ALTO | CA | 94304 | 941156365 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE BOARD OF TRUSTEES OF THE LELAND | ||||||||
| 3160 PORTER DRIVE SUITE 100 | PALO ALTO | CA | 94304 | 941156365 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE BOARD OF TRUSTEES OF THE LELAND | ||||||||
| 3160 PORTER DRIVE SUITE 100 | PALO ALTO | CA | 94304 | 941156365 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE CHILDREN'S HOSPITAL BOSTON | ||||||||
| 300 LONGWOOD AVENUE | BOSTON | MA | 02115 | 042774441 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE JOHNS HOPKINS UNIVERSITY SCHOOL | ||||||||
| JOHNS HOPKINS UNIVERSITY CENTRAL LO | CHICAGO | IL | 60693 | 520595110 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE JOHNS HOPKINS UNIVERSITY SCHOOL | ||||||||
| JOHNS HOPKINS UNIVERSITY CENTRAL LO | CHICAGO | IL | 60693 | 520595110 | 3 | $299,116 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 2150 SHATTUCK AVENUE SUITE 313 | BERKELEY | CA | 947045940 | 946002123 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 11000 KINROSS AVENUE SUITE 102 | LOS ANGELES | CA | 90095 | 956006143 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 11000 KINROSS AVENUE SUITE 102 | LOS ANGELES | CA | 90095 | 956006143 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 9500 GILMAN DRIVE MC 0009 | LA JOLLA | CA | 920930009 | 956006144 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 9500 GILMAN DRIVE MC 0009 | LA JOLLA | CA | 920930009 | 956006144 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 9500 GILMAN DRIVE MC 0009 | LA JOLLA | CA | 920930009 | 956006144 | 3 | $1,250,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 9500 GILMAN DRIVE MC 0009 | LA JOLLA | CA | 920930009 | 956006144 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 9500 GILMAN DRIVE MC 0009 | LA JOLLA | CA | 920930009 | 956006144 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 9500 GILMAN DRIVE MC 0009 | LA JOLLA | CA | 920930009 | 956006144 | 3 | $398,208 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 3333 CALIFRORNIA ST SUITE 315 | SAN FRANCISCO | CA | 941430962 | 946036493 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 3333 CALIFRORNIA ST SUITE 315 | SAN FRANCISCO | CA | 941430962 | 946036493 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 3333 CALIFRORNIA ST SUITE 315 | SAN FRANCISCO | CA | 941430962 | 946036493 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 3333 CALIFRORNIA ST SUITE 315 | SAN FRANCISCO | CA | 941430962 | 946036493 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 3333 CALIFRORNIA ST SUITE 315 | SAN FRANCISCO | CA | 941430962 | 946036493 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 3333 CALIFRORNIA ST SUITE 315 | SAN FRANCISCO | CA | 941430962 | 946036493 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 3333 CALIFRORNIA ST SUITE 315 | SAN FRANCISCO | CA | 941430962 | 946036493 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 3333 CALIFRORNIA ST SUITE 315 | SAN FRANCISCO | CA | 941430962 | 946036493 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 3333 CALIFRORNIA ST SUITE 315 | SAN FRANCISCO | CA | 941430962 | 946036493 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 3333 CALIFRORNIA ST SUITE 315 | SAN FRANCISCO | CA | 941430962 | 946036493 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 3333 CALIFRORNIA ST SUITE 315 | SAN FRANCISCO | CA | 941430962 | 946036493 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 3003 S STATE ST | ANN ARBOR | MI | 481091274 | 386006309 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 3003 S STATE ST | ANN ARBOR | MI | 481091274 | 386006309 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 3003 S STATE ST | ANN ARBOR | MI | 481091274 | 386006309 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 3003 S STATE ST | ANN ARBOR | MI | 481091274 | 386006309 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 3003 S STATE ST | ANN ARBOR | MI | 481091274 | 386006309 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 3003 S STATE ST | ANN ARBOR | MI | 481091274 | 386006309 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 3003 S STATE ST | ANN ARBOR | MI | 481091274 | 386006309 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 3003 S STATE ST | ANN ARBOR | MI | 481091274 | 386006309 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 3003 S STATE ST | ANN ARBOR | MI | 481091274 | 386006309 | 3 | $300,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 3003 S STATE ST | ANN ARBOR | MI | 481091274 | 386006309 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 3003 S STATE ST | ANN ARBOR | MI | 481091274 | 386006309 | 3 | $400,000 | ACCRUAL | RESEARCH GRANT |
| THE SCRIPPS RESEARCH INSTITUTE | ||||||||
| 10550 NORTH TORREY PINES ROAD TPC- | LA JOLLA | CA | 92037 | 330435954 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE TRUSTEES OF COLUMBIA UNIVERSITY | ||||||||
| 630 WEST 168TH STREET BOX 49 | NEW YORK | NY | 10032 | 135598093 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE TRUSTEES OF THE UNIVERSITY OF P | ||||||||
| 3451 WALNUT STREET ROOM P-221 | PHILADELPHIA | PA | 191046205 | 231352685 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE TRUSTEES OF THE UNIVERSITY OF P | ||||||||
| 3451 WALNUT STREET ROOM P-221 | PHILADELPHIA | PA | 191046205 | 231352685 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF CHICAGO | ||||||||
| 6030 S ELLIS AVENUE ROOM 114 ED- | CHICAGO | IL | 60637 | 362177139 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF CHICAGO | ||||||||
| 6030 S ELLIS AVENUE ROOM 114 ED- | CHICAGO | IL | 60637 | 362177139 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF NORTH CAROLINA AT | ||||||||
| 104 AIRPORT DRIVE SUITE 2200 CB 1 | CHAPEL HILL | NC | 275991350 | 566001393 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF NORTH CAROLINA AT | ||||||||
| 104 AIRPORT DRIVE SUITE 2200 CB 1 | CHAPEL HILL | NC | 275991350 | 566001393 | 3 | $402,524 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF TEXAS MD ANDERSON | ||||||||
| 1515 HOLCOMBE BLVD UNIT 904 | HOUSTON | TX | 77030 | 746001118 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF TEXAS MD ANDERSON | ||||||||
| 1515 HOLCOMBE BLVD UNIT 904 | HOUSTON | TX | 77030 | 746001118 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF TEXAS MD ANDERSON | ||||||||
| 1515 HOLCOMBE BLVD UNIT 904 | HOUSTON | TX | 77030 | 746001118 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF TEXAS MD ANDERSON | ||||||||
| 1515 HOLCOMBE BLVD UNIT 904 | HOUSTON | TX | 77030 | 746001118 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF TEXAS MD ANDERSON | ||||||||
| 1515 HOLCOMBE BLVD UNIT 904 | HOUSTON | TX | 77030 | 746001118 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF TEXAS MD ANDERSON | ||||||||
| 1515 HOLCOMBE BLVD UNIT 904 | HOUSTON | TX | 77030 | 746001118 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF TEXAS MD ANDERSON | ||||||||
| 1515 HOLCOMBE BLVD UNIT 904 | HOUSTON | TX | 77030 | 746001118 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF TEXAS MD ANDERSON | ||||||||
| 1515 HOLCOMBE BLVD UNIT 904 | HOUSTON | TX | 77030 | 746001118 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF TEXAS MD ANDERSON | ||||||||
| 1515 HOLCOMBE BLVD UNIT 904 | HOUSTON | TX | 77030 | 746001118 | 3 | $400,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF ALABAMA AT BIRMINGHAM | ||||||||
| 1530 3RD AVE SOUTH SUITE 1170 AB | BIRMINGHAM | AL | 352940111 | 636005396 | 3 | $300,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF ALABAMA AT BIRMINGHAM | ||||||||
| 1530 3RD AVE SOUTH SUITE 1170 AB | BIRMINGHAM | AL | 352940111 | 636005396 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF CALIFORNIA SAN DIEGO | ||||||||
| 9500 GILMAN DRIVE MC 0009 | LA JOLLA | CA | 920930009 | 952872494 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF CALIFORNIA SAN FRANC | ||||||||
| 3333 CALIFRORNIA ST SUITE 315 | SAN FRANCISCO | CA | 941430962 | 946036493 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF CALIFORNIA SAN FRANC | ||||||||
| 3333 CALIFRORNIA ST SUITE 315 | SAN FRANCISCO | CA | 941430962 | 946036493 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF CALIFORNIA SAN FRANC | ||||||||
| 3333 CALIFRORNIA ST SUITE 315 | SAN FRANCISCO | CA | 941430962 | 946036493 | 3 | $1,250,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF COLORADO DENVER | ||||||||
| PO BOX 910238 | DENVER | CO | 80291 | 846000555 | 3 | $75,000 | FMV | THERAPY ACCELERATION |
| UNIVERSITY OF COLORADO DENVER ANSC | ||||||||
| ANSCHUTZ MEDICAL CAMPUS BLDG 500 R | AURORA | CO | 80045 | 840166760 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF CONNECTICUT HEALTH CE | ||||||||
| 263 FARMINGTON AVENUE | FARMINGTON | CT | 060302806 | 571725543 | 3 | $337,033 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF FLORIDA | ||||||||
| RESEARCH GRADUATE PROGRAMS 219 G | GAINESVILLE | FL | 32610 | 596002052 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF FLORIDA | ||||||||
| RESEARCH GRADUATE PROGRAMS 219 G | GAINESVILLE | FL | 32610 | 596002052 | 3 | $379,475 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MARYLAND | ||||||||
| 3112 LEE BUIDLING | COLLEGE PARK | MD | 20742 | 526002033 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MARYLAND BALTIMORE | ||||||||
| RESEARCH ADMINISTRATION SUITE N9E1 | BALTIMORE | MD | 21201 | 526002033 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MASSACHUSETTS MEDICAL | ||||||||
| OFFICE OF RESEARCH RESEARCH FUNDIN | WORCESTER | MA | 01655 | 043167352 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MASSACHUSETTS MEDICAL | ||||||||
| OFFICE OF RESEARCH RESEARCH FUNDIN | WORCESTER | MA | 01655 | 043167352 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MASSACHUSETTS MEDICAL | ||||||||
| OFFICE OF RESEARCH RESEARCH FUNDIN | WORCESTER | MA | 01655 | 043167352 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MASSACHUSETTS MEDICAL | ||||||||
| OFFICE OF RESEARCH RESEARCH FUNDIN | WORCESTER | MA | 01655 | 043167352 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MASSACHUSETTS MEDICAL | ||||||||
| OFFICE OF RESEARCH RESEARCH FUNDIN | WORCESTER | MA | 01655 | 043167352 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MASSACHUSETTS MEDICAL | ||||||||
| OFFICE OF RESEARCH RESEARCH FUNDIN | WORCESTER | MA | 01655 | 043167352 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MINNESOTA TWIN CITIE | ||||||||
| OFFICE OF SPONSORED PROJECTS ADMINI | MINNEAPOLIS | MN | 55455 | 416007513 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF NEBRASKA MEDICAL CENT | ||||||||
| 985100 NEBRASKA MEDICAL CENTER | OMAHA | NE | 681985100 | 470049123 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF NORTH CAROLINA AT CHA | ||||||||
| 104 AIRPORT DRIVE SUITE 2200 CB 1 | CHAPEL HILL | NC | 275991350 | 566001393 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF PENNSYLVANIA | ||||||||
| 3451 WALNUT STREET ROOM P-221 | PHILADELPHIA | PA | 191046205 | 231352685 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF PENNSYLVANIA - SCHOOL | ||||||||
| 295 JOHN MORGAN BUILDING 3620 HAMI | PHILADELPHIA | PA | 19104 | 231352685 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF ROCHESTER | ||||||||
| OFFICE OF RESEARCH PROJECT ADMINI | ROCHESTER | NY | 14627 | 160743209 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF SOUTH CAROLINA | ||||||||
| 901 SUMTER STREET 5TH FL | COLUMBIA | SC | 29208 | 576001153 | 3 | $21,945 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF SOUTHERN CALIFORNIA | ||||||||
| 2250 ALCAZAR STREET CONTRACTS GR | LOS ANGELES | CA | 90033 | 951642394 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF SOUTHERN CALIFORNIA | ||||||||
| 2250 ALCAZAR STREET CONTRACTS GR | LOS ANGELES | CA | 90033 | 951642394 | 3 | $400,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF TEXAS SOUTHWESTERN ME | ||||||||
| 5323 HARRY HINES BLVD | DALLAS | TX | 753909020 | 756002868 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF TEXAS SOUTHWESTERN ME | ||||||||
| 5323 HARRY HINES BLVD | DALLAS | TX | 753909020 | 756002869 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF UTAH | ||||||||
| 201 S PRESIDENTS CIRCLE RM 145 | SALT LAKE CITY | UT | 841129003 | 876000525 | 3 | $352,404 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF UTAH | ||||||||
| 201 S PRESIDENTS CIRCLE RM 145 | SALT LAKE CITY | UT | 841129003 | 876000525 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF VIRGINIA | ||||||||
| DIRECTOR OFFICE OF SPONSORED PROGRA | CHARLOTTESVILLE | VA | 22904 | 237173411 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF WASHINGTON | ||||||||
| UW GRANTS CONTRACT SERVICES 3935 | SEATTLE | WA | 98195 | 943079432 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF WASHINGTON | ||||||||
| UW GRANTS CONTRACT SERVICES 3935 | SEATTLE | WA | 98195 | 943079432 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| VANDERBILT UNIVERSITY MEDICAL CENTE | ||||||||
| 3319 WEST END AVENUE SUITE 800 | NASHVILLE | TN | 37232 | 620476822 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| VIRGINIA COMMONWEALTH UNIVERSITY | ||||||||
| SPONSORED PROGRAMS ADMINISTRATION | RICHMOND | VA | 232980568 | 012201761 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| WAKE FOREST UNIVERSITY | ||||||||
| CONTROLLERS OFFICE MEDICAL CENTER | WINSTONSALEM | NC | 27157 | 560532138 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| WASHINGTON UNIVERSITY SCHOOL OF MED | ||||||||
| SPONSORED PROJECTS ACCOUNTING 700 | ST LOUIS | MO | 63110 | 430653611 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| WASHINGTON UNIVERSITY SCHOOL OF MED | ||||||||
| SPONSORED PROJECTS ACCOUNTING 700 | ST LOUIS | MO | 63110 | 430653611 | 3 | $399,756 | ACCRUAL | RESEARCH GRANT |
| WEILL CORNELL MEDICAL COLLEGE | ||||||||
| 1300 YORK AVENUE BOX 89 | NEW YORK | NY | 100654805 | 131623978 | 3 | $383,867 | ACCRUAL | RESEARCH GRANT |
| WEILL MED COLLEGE OF CORNELL | ||||||||
| 1300 YORK AVE | NEW YORK | NY | 10065 | 131623978 | 3 | $600,000 | FMV | THERAPY ACCELERATION |
| WHITEHEAD INSTITUTE FOR BIOMEDICAL | ||||||||
| 9 CAMBRIDGE CENTER | CAMBRIDGE | MA | 021421479 | 061043412 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| WHITEHEAD INSTITUTE FOR BIOMEDICAL | ||||||||
| 9 CAMBRIDGE CENTER | CAMBRIDGE | MA | 021421479 | 061043412 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| YALE UNIVERSITY | ||||||||
| OFFICE OF SPONSORED PROJECTS PO BO | NEW HAVEN | CT | 065208327 | 060646973 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| CELATOR PHARMACEUTICALS INC | ||||||||
| 200 PRINCETON SOUTH CORPORATE CENTE | EWING | NJ | 08628 | 202680869 | $274,256 | FMV | THERAPY ACCELERATION | |
| CELATOR PHARMACEUTICALS INC | ||||||||
| 200 PRINCETON SOUTH CORPORATE CENTE | EWING | NJ | 08628 | 202680869 | $900,000 | FMV | THERAPY ACCELERATION | |
| CONSTELLATION PHARMACEUTICALS | ||||||||
| 215 FIRST STREET | CAMBRIDGE | MA | 02142 | 261741721 | $775,000 | FMV | THERAPY ACCELERATION | |
| CONSTELLATION PHARMACEUTICALS | ||||||||
| 215 FIRST STREET | CAMBRIDGE | MA | 02142 | 261741721 | $775,000 | FMV | THERAPY ACCELERATION | |
| FOX CHASE CANCER CENTER | ||||||||
| 604 COTTMAN AVE | CHELTENHAM | PA | 19012 | 231352156 | $29,000 | FMV | THERAPY ACCELERATION | |
| GOODWIN PROCTER LLP | ||||||||
| 53 STATE STREET | BOSTON | MA | 02109 | 041378465 | $345,000 | FMV | THERAPY ACCELERATION | |
| GOODWIN PROCTOR LLP | ||||||||
| 53 STATE STREET | BOSTON | MA | 02109 | 041378465 | $345,000 | FMV | THERAPY ACCELERATION | |
| MILESTONE1 KITE PHARMA | ||||||||
| 2225 COLORADO AVE | SANTA MONICA | CA | 90404 | 271524986 | $500,000 | FMV | THERAPY ACCELERATION | |
| NANOSYN INC | ||||||||
| 3100 CENTRAL EXPRESSWAY | SANTA CLARA | CA | 95051 | 860909295 | $264,490 | FMV | THERAPY ACCELERATION | |
| STEMLINE THERAPEUTICS INC | ||||||||
| 750 LEXINGTON AVE | NEW YORK | NY | 10022 | 450522567 | $500,000 | FMV | THERAPY ACCELERATION | |
| STEMLINE THERAPEUTICS INC | ||||||||
| 750 LEXINGTON AVE | NEW YORK | NY | 10022 | 450522567 | $1,000,000 | FMV | THERAPY ACCELERATION | |
| VALOR BIOTHERAPEUTICS | ||||||||
| 8800 HSC PARKWAY | BRYAN | TX | 77807 | 461883738 | $100,000 | FMV | THERAPY ACCELERATION | |
| VALOR BIOTHERAPEUTICS | ||||||||
| 8800 HSC PARKWAY | BRYAN | TX | 77807 | 461883738 | $200,000 | FMV | THERAPY ACCELERATION | |
| VALOR BIOTHERAPEUTICS | ||||||||
| 8800 HSC PARKWAY | BRYAN | TX | 77807 | 461883738 | $100,000 | FMV | THERAPY ACCELERATION | |
| VALOR BIOTHERAPEUTICS | ||||||||
| 8800 HSC PARKWAY | BRYAN | TX | 77807 | 461883738 | $200,000 | FMV | THERAPY ACCELERATION | |
| VALOR BIOTHERAPEUTICS | ||||||||
| 8800 HSC PARKWAY | BRYAN | TX | 77807 | 461883738 | $1,000,000 | FMV | THERAPY ACCELERATION | |
| VELESCO PHARMACEUTICAL SERVICE | ||||||||
| 46701 N COMMERCE CENTER DRIVE | PLYMOUTH | MI | 48170 | 261330932 | $22,920 | FMV | THERAPY ACCELERATION | |
| VELESCO PHARMACEUTICAL SERVICE | ||||||||
| 46701 N COMMERCE CENTER DRIVE | PLYMOUTH | MI | 48170 | 261330932 | $20,219 | FMV | THERAPY ACCELERATION | |
| VELESCO PHARMACEUTICAL SERVICE | ||||||||
| 46701 N COMMERCE CENTER DRIVE | PLYMOUTH | MI | 48170 | 261330932 | $9,018 | FMV | THERAPY ACCELERATION | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 102 | Total501c3OrgCnt |
| Total Other Org | 9 | TotalOtherOrgCnt |
Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp (10 entries)
| Grant TypeGrantTypeTxt | RecipientRecipientCnt | Cash GrantCashGrantAmt |
|---|---|---|
| PATIENT FINANCIAL AID | 808 | $111,525 |
| COPAY ASSISTANCE CLL | 2168 | $3,686,309 |
| COPAY ASSISTANCE LYMPHOMA | 7746 | $8,791,634 |
| COPAY ASSISTANCE MDS | 1603 | $3,592,561 |
| COPAY ASSISTANCE MYELOMA | 6658 | $22,228,870 |
| COPAY ASSISTANCE MANTEL | 500 | $1,305,000 |
| COPAY ASSISTANCE CML | 1191 | $2,006,405 |
| COAPY ASSISTANCE ALL | 34 | $80,550 |
| COPAY ASSISTANCE WALDENST | 22 | $114,152 |
| PATIENT TRAVEL ASSISTNCE | 633 | $318,255 |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | SCHEDULE I, PAGE 1, PART I, LINE 2 | FormAndLineReferenceDesc |
| Explanation | FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. PATIENT FINANCIAL AID: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR MANY EXPENSES RELATED TO THEIR TREATMENT. SOMETIMES PATIENTS HAVE TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE TREATMENT EXPENSES. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS HAS ESTABLISHED A PATIENT FINANCIAL AID PROGRAM THAT PROVIDES APPLICANTS, WHO RESIDE IN THE US AND HAVE A BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. CO-PAY ASSISTANCE: PATIENT APPLICATIONS ARE PROCESSED ON A FIRST COME, FIRST SERVED BASIS. ELIGIBLE PATIENTS MUST RESIDE IN THE UNITED STATES OR PUERTO RICO, HAVE A PROGRAM COVERED BLOOD CANCER DIAGNOSIS CONFIRMED BY A PHYSICIAN, MAINTAIN MEDICAL/PRESCRIPTION INSURANCE AND HAVE HOUSEHOLD INCOME AT OR BELOW 500% OF THE US FEDERAL POVERTY LEVEL AS ADJUSTED BY HOUSEHOLD SIZE AND COST OF LIVING INDEX. PATIENTS MUST PROVIDE PROOF OF INSURANCE AND INCOME. QUALIFYING PATIENTS ARE APPROVED FOR A TWELVE MONTH COVERAGE PERIOD. PATIENT TRAVEL ASSISTANCE: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR TRANSPORTATION TO GET TO THEIR PROVIDERS, E.G. DOCTORS, HOSPITALS, TRANSPLANT CENTERS, AND RESEARCH OR CLINICAL TRIAL CENTERS. SOMETIMES PATIENTS HAVE TO TRAVEL OUT-OF-STATE TO GET THEIR PRESCRIBED AND RECOMMENDED TREATMENTS, OFTENTIMES RESULTING IN PATIENTS HAVING TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS ESTABLISHED THE TRAVEL ASSISTANCE PROGRAM WHICH PROVIDES APPLICANTS, WHO ARE US CITIZENS OR PERMANENT RESIDENTS, HAVE AN ANNUAL INCOME AT OR BELOW 500% OF THE FEDERAL POVERTY LEVEL (FPL) AND HAVE A CONFIRMED BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Compensation Committee | Yes (X) | CompensationCommitteeInd |
| Independent Consultant | Yes (X) | IndependentConsultantInd |
| Form990 Of Other Organizations | Yes (X) | Form990OfOtherOrganizationsInd |
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | Yes (true) | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | Yes (true) | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | false | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | false | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | false | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | false | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | false | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | Yes (true) | AnyNonFixedPaymentsInd |
| Initial Contract Exception | false | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (11 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt |
|---|---|---|---|---|---|---|---|
| LOUIS J DEGENNARO | |||||||
| PRESIDENT & CEO | $433,871 | $23,963 | $84,300 | $28,674 | $570,808 | ||
| ROSEMARIE A LOFFREDO | |||||||
| EVP-CAO & CFO | $300,560 | $11,632 | $10,150 | $14,666 | $337,008 | ||
| GORDON MILLER JR | |||||||
| SVP FINANCE | $210,677 | $9,439 | $19,400 | $27,940 | $267,456 | ||
| MARK ROITHMAYR | |||||||
| EVP-CHIEF DEVEL OFF | $343,206 | $10,554 | $17,976 | $32,057 | $403,793 | ||
| GEORGE J OMIROS-TERM APR15 | |||||||
| EVP-CHIEF CAMP&FIELD | $306,618 | $11,698 | $28,111 | $22,014 | $368,441 | ||
| BRIAN ROSEN - TERM FEB15 | |||||||
| CHIEF POLICY & ADVOC | $255,063 | $12,547 | $18,776 | $10,873 | $322,259 | $25,000 | $5,594 |
| LEE M GREENBERGER | |||||||
| SVP & CHIEF SCIENTIF | $272,769 | $11,397 | $10,006 | $32,899 | $327,071 | ||
| JEFFREY COMO-TERM DEC14 | |||||||
| CHIEF INFORM.OFFICER | $81,125 | $307,345 | $20,518 | $1,389 | $460,377 | $50,000 | |
| LISA STOCKMON - TERM SEPT14 | |||||||
| EVP-CHIEF MARK.OFFIC | $219,789 | $59,141 | $8,750 | $12,609 | $300,289 | $18,749 | |
| GABRIELLE URQUHART-TERM JUN15 | |||||||
| REGIONAL VP | $210,453 | $1,923 | $9,653 | $10,294 | $257,323 | $25,000 | |
| JOHN E WALTER - TERM FEB14 | |||||||
| FORMER PRES & CEO | $54,230 | $785,660 | $1,458 | $22,896 | $864,244 | $156,240 | |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| SCHEDULE J, PAGE 1, PART I, LINE 4 | LOUIS J. DEGENNARO 0 50,000 0 JEFFREY COMO-TERM DEC14 130,452 0 0 JOHN E. WALTER - TERM FEB14 592,172 0 0 |
| SCHEDULE J, PAGE 1, PART I, LINE 7 | BONUSES WERE PAID BASED ON THE ACHIEVEMENT OF THE OVERALL ORGANIZATION'S OPERATING PLAN, EMPLOYEE INDIVIDUAL PERFORMANCE AND OTHER METRICS. BONUSES WERE CAPPED ACCORDING TO LLS'S POLICY. THESE AMOUNTS ARE REPORTED ON SCHEDULE J PART II, COLUMN (B)(II). |
Schedule M IRS990ScheduleM
Securities Publicly Traded SecuritiesPubliclyTradedGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 141 | ContributionCnt |
| Noncash Contributions Rpt F990 | $969,388 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | MARKET VALUE | MethodOfDeterminingRevenuesTxt |
Food Inventory FoodInventoryGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 48 | ContributionCnt |
Other Non Cash Contri Table OtherNonCashContriTableGrp (2 entries)
| Non Cash CheckboxNonCashCheckboxInd | DescDesc | ContributionContributionCnt |
|---|---|---|
| Yes (X) | PRINTED ITEMS | 11 |
| Yes (X) | VARIOUS | 48 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Any Property That Must Be Held | false | AnyPropertyThatMustBeHeldInd |
| Review Process Unusual NC Gifts | Yes (true) | ReviewProcessUnusualNCGiftsInd |
| Third Parties Used | false | ThirdPartiesUsedInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | SCHEDULE M, PAGE 2, PART II | FormAndLineReferenceDesc |
| Explanation | PART I, COLUMN (B) LLS IS REPORTING THE NUMBER OF CONTRIBUTIONS FOR EACH OF THE ITEMS IN PART I, NOT THE NUMBER OF INDIVIDUAL ITEMS. PART I, LINE 33 - EXPLANATION FOR NOT REPORTING REVENUE LLS ONLY RECORDS DONATED SECURITIES AS REVENUE. ALL OTHER ITEMS FOR WHICH COLUMN A IS CHECKED ARE NOT RECORDED AS REVENUE OR EXPENSE BECAUSE THEY WOULD NOT HAVE BEEN PURCHASED HAD THEY NOT BEEN DONATED, AND ARE IMMATERIAL IN AMOUNT RELATIVE TO THE STATEMENTS OF LLS. | ExplanationTxt |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (16 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PAGE 2, PART III, LINE 4A | WE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2015, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 7 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 65 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, AND, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. - ADCETRIS WAS APPROVED IN 2011, AND IN JANUARY 2012. IT IS AN ANTIBODY- DRUG CONJUGATE THAT COMBINES AN ANTI-CD30 ANTIBODY AND THE CYTOTOXIC DRUG MONOMETHYL AURISTATIN E (MMAE). IT IS AN ANTI-NEOPLASTIC AGENT USED IN THE TREATMENT OF HODGKIN LYMPHOMA AFTER FAILURE OF AUTOLOGOUS STEM CELL TRANSPLANT OR THOSE WHO ARE NOT ELIGIBLE FOR ASCT AFTER FAILURE OF AT LEAST 2 MUTIAGEN CHEMOTHERAPY REGIMENS. ADCETRIS WAS ALSO APPROVED FOR SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA WITH FAILURE OF AT LEAST ONE PRIOR TREATMENT. - GAZYVA IS A HUMANIZED MONOCLONAL ANTIBODY USED AS A COMBINATION TREATMENT WITH CHLORAMBUCIL TO TREAT PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA. IT WAS APPROVED BY THE FDA IN NOVEMBER 2013 AND BY THE EHA IN JULY 2014. - IMBRUVICA IS AN ORAL SMALL MOLECULE INHIBITOR AGIANST BTK KINASE. IT WAS FIRST APPROVED BY THE US FDA ON NOVEMBER 13, 2013 FOR THE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS WHO HAVE RECIEVED AT LEAST ONE PRIOR TREATMENT. ON FEB. 12, 2014 THE US FDA EXPANDED THE APPROVED USE OF THE DRUG TO CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ADDITIONALLY, IT RECEIVED FURTHER EXPANSION TO TREAT 17P DELETION IN CLL WITH OR WITHOUT PRIOR THERAPY. - ZYDELIG IS AN ORAL SMALL MOLECULE INHIBITOR THAT BLOCKS THE DELTA ISOFORM OF THE ENZYME PHOSPHOINOSITIDE 3-KINASE. IT WAS APPROVED BY THE FDA IN JULY 2014 TO TREAT RELAPSED/REFRACTORY CLL IN COMBINATION WITH RITUXAN. IT WAS ALSO APPROVED TO USE AS A MONOTHERAPY FOR RELAPSED MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2015, FOR THE FOURTH YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN SIX OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES FOR PATIENTS WITH NON- CUTANEOUS T-CELL LYMPHOPROLIFERATIVE DISORDERS - DEVELOP NOVEL TARGETED THERAPIES FOR CLL PATIENTS, WITH REAL CURATIVE POTENTIAL - DEVELOP NOVEL TREATMENT STRATEGIES FOR MDS AND AML PATIENTS - DEVELOP NOVEL TARGETED THERAPIES FOR PATIENTS WITH HIGH-RISK MYELOMA - DEVELOPMENT OF NEW-TARGETED THERAPIES FOR INDOLENT LYMPHOMA PATIENTS - DEFINE GENETIC/MOLECULAR PREDISPOSITIONS TO LONG-TERM AND LATE-TERM EFFECTS ASSOCIATED WITH STANDARD THERAPIES IN PEDIATRIC ALL AND APPLY THIS INFORMATION TO IMPROVE PATIENT OUTCOMES. THE THERAPY ACCELERATION PROGRAM THIS STRATEGIC INITIATIVE WAS LAUNCHED IN 2007 TO MOVE NEW TREATMENTS AND DIAGNOSTICS THROUGH PRECLINICAL DEVELOPMENT AND CLINICAL TRIALS, FASTER. USING MILESTONE-DRIVEN CONTRACTS AND WORKING IN CONCERT WITH ACADEMIC INVESTIGATORS, MEDICAL CENTERS AND COMPANIES, LLS IS FURTHER BRIDGING THE GAP BETWEEN DISCOVERY AND HUMAN APPLICATIONS TO INCREASE THE LIKELIHOOD THAT NOVEL, POSSIBLY BREAKTHROUGH, TREATMENTS WILL BE AVAILABLE TO PATIENTS AS SOON |
| FORM 990, PAGE 2, PART III, LINE 4B | A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL; AND CURRENT AND ACCURATE INFORMATION ABOUT SYMPTOMS, RISK FACTORS AND TREATMENT. PUBLICATIONS AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS THROUGH THE INFORMATION RESOURCE CENTER AND LLS CHAPTERS. MANY MATERIALS ARE ALSO AVAILABLE TO VIEW AND DOWNLOAD AT WWW.LLS.ORG/RESOURCECENTER. DOWNLOADABLE MATERIALS ARE AVAILABLE IN ENGLISH, SPANISH AND FRENCH. - 705,326 PRINTED BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS DISTRIBUTED IN 2015. FINANCIAL ASSISTANCE IN 2015, A COMBINED 42,235,261 WAS DISBURSED TO PATIENTS THROUGH THE LLS PATIENT FINANCIAL AID (111,525),CO-PAY ASSISTANCE PROGRAMS (41,805,481) AND THE LLS NATIONAL PATIENT TRAVEL ASSISTANCE PROGRAM (318,255). CO-PAY ASSISTANCE PROGRAM THIS CO-PAY ASSISTANCE PROGRAM HELPS PATIENTS WITH MANY KINDS OF BLOOD CANCERS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO-PAYMENT OBLIGATIONS RELATED TO TREATING THEIR CANCER. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUND AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. FOR MORE INFORMATION CALL, (877) LLS-COPAY (877) 557-2672 OR VISIT WWW.LLS.ORG/COPAY. - 19,922 PATIENTS RECEIVED LLS CO-PAY ASSISTANCE IN 2015 COMMUNITY PROGRAMS EACH LLS CHAPTER OFFICE IS STAFFED WITH A PATIENT SERVICES MANAGER (PSM) WHO OVERSEES SERVICES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PSMS ARE HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING OR SOCIAL WORK. PSMS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS. COMMUNITY-BASED EDUCATION AND OUTREACH, SUPPORT AND PUBLIC POLICY AND ADVOCACY PROGRAMS ARE AVAILABLE. PATIENT EDUCATION PROGRAMS: IN 2015 WE CONDUCTED 221 LOCAL PATIENT EDUCATION PROGRAMS TO A TOTAL OF 9,807 ATTENDEES. THESE PROGRAMS RANGED FROM DISEASE SPECIFIC TOPICS TO THOSE OF SURVIVORSHIP. OF THE TOTAL ATTENDING THESE LOCAL EDUCATION PROGRAMS, A MAJORITY WERE PATIENTS AND CAREGIVERS (6,872 ATTENDEES) BUT IMPORTANTLY, MANY (2,404 ATTENDEES) WERE HEALTHCARE PROFESSIONALS. BLOOD CANCER CONFERENCES: LLS WORKS TO ELEVATE OUR VISIBILITY IN COMMUNITIES WE SERVE BY HOSTING LARGER-SCALE CONFERENCES, GEARED FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. THESE EVENTS ARE A CATALYST FOR BRINGING MANY DEDICATED PEOPLE TOGETHER TO FOCUS ON BLOOD CANCER AWARENESS, INFORMATION AND THE LATEST ADVANCES IN MEDICAL SCIENCE. THEY ARE ALSO AN IMPORTANT SOURCE OF CONTINUING EDUCATION FOR MANY HEALTHCARE PROFESSIONALS. IN 2015, 25 BCC CONFERENCES WERE HELD WITH TOTAL ATTENDANCE OF 6,589. 2,965 WERE PATIENTS, 1,511 CAREGIVERS, 1,001 NURSES, 181 SOCIAL WORKS, 128 MEDICAL DOCTORS, AND 628 "OTHER" HEALTHCARE PROFESSIONALS SERVING THE UNDERSERVED: IN 2015, WE OFFERED 68 SPECIAL PROGRAMS TO PEOPLE WHO OFTEN DON'T HAVE THE SAME ACCESS TO INFORMATION AND SUPPORT AS OTHERS MIGHT HAVE. BREAKING DOWN ACCESS BARRIERS IN UNDERREPRESENTED POPULATIONS MEANS BLOOD CANCER PATIENTS GET THE INFORMATION AND SUPPORT THEY NEED. THIS OUTREACH BROUGHT IMPORTANT DISEASE TREATMENT INFORMATION TO MORE THAN 5,500 PEOPLE IN COMMUNITIES WE SERVE. OF THIS, 3,870 WERE PATIENTS AND CAREGIVERS, JOINED BY 1,126 HEALTHCARE PROFESSIONALS. MYELOPROLIFERATIVE NEOPLASMS OR MPN: IN 2015, LLS WAS ABLE TO OFFER SPECIALIZED MYELOPROLIFERATIVE NEOPLASMS OR MPN EDUCATION PROGRAMS IN FOUR COMMUNITIES TO A TOTAL OF 70 PATIENTS AND CAREGIVERS AND 9 HEALTHCARE PROFESSIONALS. IN ADDITION, LLS PROVIDED COMMUNITY-BASED EDUCATION CONCERNING THE LATEST CLINICAL TRIALS INFORMATION TO 634 PATIENTS AND CAREGIVERS, WHO WERE JOINED BY 286 HEALTHCARE PROFESSIONALS. FAMILY SUPPORT GROUPS: THROUGHOUT THE US, IN 2015, LLS SUPPORTED OR HOSTED 296 REGISTERED FAMILY SUPPORT GROUP MEETINGS FOR PATIENTS AND THEIR FAMILIES. GROUPS ARE GUIDED BY TWO VOLUNTEER ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. LLS SUPPORT GROUPS ARE THE PERFECT PLACE TO TALK WITH OTHER PEOPLE AFFECTED BY BLOOD CANCERS, INCLUDING PATIENTS, FAMILY MEMBERS AND CAREGIVERS. THE GROUPS PROVIDE MUTUAL SUPPORT AND OFFER THE OPPORTUNITY TO DISCUSS ANXIETIES AND CONCERNS WITH OTHERS WHO SHARE THE SAME EXPERIENCES. THIS SHARING STRENGTHENS THE FAMILY BOND AND ENHANCES EVERYONE'S ABILITY TO COPE WITH CANCER. PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM: FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT-VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE NEW PATIENT TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS. - 1,476 FIRST CONNECTIONS ACROSS THE US IN 2015. |
| FORM 990, PAGE 2, PART III, LINE 4C | PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 9 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. - 31,511 INQUIRIES MADE TO OUR INFORMATION SPECIALISTS, AND 30,871 INQUIRIES MADE TO OUR PATIENT ACCESS STAFF ACROSS THE COUNTRY IN 2015. THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO THEIR LOCATION TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING CO-PAY ASSISTANCE, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH AND SPANISH, AND CLINICAL-TRIAL SEARCHES VIA AN ONLINE CLINICAL- TRIAL SEARCH SERVICE THAT OFFERS PATIENTS AND CAREGIVERS IMMEDIATE ACCESS TO LISTINGS OF BLOOD CANCER CLINICAL TRIALS. PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS CAN INTERACT WITH LLS AND ONE ANOTHER THROUGH SOCIAL NETWORKING, PODCASTS AND ENEWSLETTERS. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS LLS SPONSORS TELEPHONE AND WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES. IN 2015, 9 LLS NATIONAL EDUCATION PROGRAMS FEATURED DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT SUPPORT AND TREATMENT OPTIONS FROM WORLD RENOWNED CLINICAL EXPERTS. OPPORTUNITIES ARE PROVIDED TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. THESE PROGRAMS OFFER CONTINUING EDUCATION CREDITS FOR NURSES AND SOCIAL WORKERS. LLS ALSO SPONSORS A RANGE OF PROFESSIONAL EDUCATION PROGRAMS. RECENT PROGRAMS EXPLORED THE ADMINISTRATION AND MANAGEMENT OF CURRENT THERAPIES FOR HEMATOLOGIC MALIGNANCIES AND COMMUNICATION AMONG PRIMARY CARE PROVIDERS AND HEMATOLOGISTS/ONCOLOGISTS IN MANAGING PATIENTS WITH HEMATOLOGIC CANCER. UPCOMING PROGRAMS ARE POSTED AT WWW.LLS.ORG/PROGRAMS AND ARCHIVES OF PAST PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PASTPROGRAMS. PROFESSIONAL EDUCATION PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PROFESSIONALED. LLS ALSO OFFERS DISEASE-SPECIFIC WEBCASTS PRESENTED BY WORLD RENOWNED CLINICAL EXPERTS. THESE CAN BE ACCESSED AT WWW.LLS.ORG/WEBCASTS. |
| FORM 990, PAGE 2, PART III, LINE 4D | D) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. |
| FORM 990, PART V, LINE 4B | CANADA |
| FORM 990, PAGE 6, PART VI, LINE 6 | THE MEMBERS OF LLS CONSIST OF ONE ELECTED REPRESENTATIVE FROM EACH CHAPTER. |
| FORM 990, PAGE 6, PART VI, LINE 7A | THE BOARD OF REPRESENTATIVES (REPRESENTING THE CHAPTERS) ELECTS THE MEMBERS OF LLS'S GOVERNING BODY, ITS NATIONAL BOARD OF DIRECTORS. |
| FORM 990, PAGE 6, PART VI, LINE 7B | SIGNIFICANT DECISIONS AFFECTING THE CHAPTERS REQUIRE AN APPROVING VOTE BY THE CHAPTER DELEGATES. DECISIONS NOT SIGNIFICANTLY AFFECTING THE CHAPTERS DO NOT REQUIRE APPROVAL FROM THE CHAPTER DELEGATES. |
| FORM 990, PAGE 6, PART VI, LINE 11B | THE FORM 990 WAS PREPARED BY THE LLS FINANCE DEPARTMENT AND WAS REVIEWED BY THE CAO & CFO, SR. VICE PRESIDENT OF FINANCE, AND KPMG FOR COMMENT AND SUGGESTED REVISIONS. THE FORM 990 WAS THEN PROVIDED TO THE AUDIT COMMITTEE, WHICH IS A COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWED THE 990 AND PROVIDED INPUT PRIOR TO FILING. THE FINAL DRAFT FORM 990 WAS PROVIDED TO THE ENTIRE BOARD OF DIRECTORS PRIOR TO FILING BY POSTING THE FORM ON AN INTRANET WEBSITE. |
| FORM 990, PAGE 6, PART VI, LINE 12C | ALL EMPLOYEES, BOARD OF DIRECTORS MEMBERS, BOARD OF REPRESENTATIVES MEMBERS, CHAPTER BOARD MEMBERS, FAMILY SUPPORT GROUP FACILITATORS, AND TNT COACHES ARE REQUIRED TO REVIEW THE CONFLICT OF INTEREST POLICY ON AN ANNUAL BASIS AND SUBMIT A SIGNED FORM ACKNOWLEDGING THAT THEY HAVE REVIEWED THE POLICY AND DISCLOSED ANY CONFLICTS OF INTEREST. ALL FORMS ARE COLLECTED AND THE AUDIT COMMITTEE REVIEWS ANY FORMS DISCLOSING A POSSIBLE CONFLICT OF INTEREST AND DETERMINES WHETHER OR NOT A CONFLICT EXISTS. PART VI, LINE 12 C: ALL EMPLOYEES, BOARD OF DIRECTORS MEMBERS, BOARD OF REPRESENTATIVES ARE RECUSED FROM ANY DISCUSSION WHERE A CONFLICT OF INTEREST EXISTS. ANY QUESTIONS REGARDING COI WILL GO TO THE AUDIT COMMITTEE. |
| FORM 990, PAGE 6, PART VI, LINE 15A | THE EXECUTIVE COMMITTEE COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS REVIEWS AND MONITORS THE CHIEF EXECUTIVE OFFICER'S PERFORMANCE AND COMPENSATION. IN 2015 THE COMMITTEE OBTAINED A SURVEY OF OTHER NOT- FOR-PROFIT ORGANIZATIONS' COMPENSATION RANGES AND SET THE CHIEF EXECUTIVE'S SALARY COMMENSURATELY. THE COMMITTEE MET AND REVIEWED THE COMPENSATION PACKAGE BUT IT WAS NOT INCLUDED IN THE COMMITTEE MINUTES. |
| FORM 990, PAGE 6, PART VI, LINE 15B | THE EXECUTIVE COMMITTEE COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS REVIEWS AND MONITORS THE CHIEF EXECUTIVE OFFICER'S PERFORMANCE AND COMPENSATION. IN 2015 THE COMMITTEE OBTAINED A SURVEY OF OTHER NOT- FOR-PROFIT ORGANIZATIONS' COMPENSATION RANGES AND SET THE CHIEF EXECUTIVE'S SALARY COMMENSURATELY. THE COMMITTEE MET AND REVIEWED THE COMPENSATION PACKAGE BUT IT WAS NOT INCLUDED IN THE COMMITTEE MINUTES. |
| FORM 990, PAGE 6, PART VI, LINE 17 | ILLINOIS, INDIANA, KANSAS, KENTUCKY, LOUISIANA, MASSACHUSETTS, MARYLAND, MAINE, MICHIGAN, MINNESOTA, MISSOURI, MISSISSIPPI, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NEBRASKA, NEW YORK, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, PUERTO RICO, RHODE ISLAND, SOUTH CAROLINA, TENNESSEE, UTAH, VIRGINIA, WASHINGTON, WISCONSIN, WEST VIRGINIA |
| FORM 990, PAGE 6, PART VI, LINE 19 | THE LEUKEMIA & LYMPHOMA SOCIETY, INC. MAKES ITS ANNUAL FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE AT WWW.LLS.ORG. ITS GOVERNING DOCUMENTS ARE MADE AVAILABLE FOR PUBLIC INSPECTION. ANY IDENTIFIED CONFLICTS OF INTEREST ARE DISCLOSED IN THE 990. |
| FORM 990, PART XI, LINE 9 | LLS CANADA REVENUE 10,501,177 LLS CANADA GAIN ON INVESTMENT 177,817 LLS CANADA EXPENSES -10,122,744 FOREIGN CURRENCY TRANSLATION -530,316 |
| FORM 990, PART XI, LINE 9 | CANADA OPENING NET ASSETS ADJUSTMENTS 133,047 FINANCIAL STATEMENTS ROUNDING -61 LLS CANADA CHANGE IN NET ASSET -25,936 INC. |
Schedule R IRS990ScheduleR
Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (3 entries)
| Address Line1ForeignAddress/AddressLine1Txt | CityForeignAddress/CityNm | CountryForeignAddress/CountryCd | Foreign PostalForeignAddress/ForeignPostalCd | Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile Foreign CountryLegalDomicileForeignCountryCd | Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt | Controlled OrganizationControlledOrganizationInd | Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | EINEIN | Legal Domicile StateLegalDomicileStateCd | Exempt Code SectionExemptCodeSectionTxt | Public Charity StatusPublicCharityStatusTxt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| THE LLS OF CANADA | |||||||||||||||
| 804 2 LANSING SQUARE | TORONTO | CA | M2J4P8 | PART VII | CA | NA | false | ||||||||
| THE LLS RESEARCH PROGRAMS INC | |||||||||||||||
| PART VII | LLS INC | Yes (true) | 1311 MAMARONECK AVENUE | WHITE PLAINS | NY | 10605 | 133470494 | DE | 501C3 | 11B | |||||
| THE LLS RESEARCH FOUNDATION | |||||||||||||||
| PART VII | LLS INC | Yes (true) | 1311 MAMARONECK AVENUE | WHITE PLAINS | NY | 10605 | 133709252 | DE | 501C3 | 11B | |||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Receipt Of Int Annts Rnts Rylts | false | ReceiptOfIntAnntsRntsRyltsInd |
| Gift Grnt Or Cap Contri To Oth Org | false | GiftGrntOrCapContriToOthOrgInd |
| Gift Grnt Cap Contri From Oth Org | Yes (true) | GiftGrntCapContriFromOthOrgInd |
| Loans Or Guarantees To Other Org | Yes (true) | LoansOrGuaranteesToOtherOrgInd |
| Loans Or Guarantees From Oth Org | false | LoansOrGuaranteesFromOthOrgInd |
| Div Related Organization | false | DivRelatedOrganizationInd |
| Asset Sale To Other Org | false | AssetSaleToOtherOrgInd |
| Asset Purchase From Other Org | false | AssetPurchaseFromOtherOrgInd |
| Asset Exchange | false | AssetExchangeInd |
| Rental Of Facilities To Oth Org | false | RentalOfFacilitiesToOthOrgInd |
| Rental Of Fclts From Oth Org | false | RentalOfFcltsFromOthOrgInd |
| Perform Of Services For Oth Org | false | PerformOfServicesForOthOrgInd |
| Perform Of Services By Other Org | false | PerformOfServicesByOtherOrgInd |
| Sharing Of Facilities | Yes (true) | SharingOfFacilitiesInd |
| Paid Employees Sharing | Yes (true) | PaidEmployeesSharingInd |
| Reimbursement Paid To Other Org | false | ReimbursementPaidToOtherOrgInd |
| Reimbursement Paid By Other Org | false | ReimbursementPaidByOtherOrgInd |
| Transfer To Other Org | false | TransferToOtherOrgInd |
| Transfer From Other Org | false | TransferFromOtherOrgInd |
Transactions Related Org TransactionsRelatedOrgGrp (2 entries)
| Transaction TypeTransactionTypeTxt | InvolvedInvolvedAmt | Method Of Amount DeterminationMethodOfAmountDeterminationTxt |
|---|---|---|
| THE LEUKEMIA & LYMPHOMA SOCIETY | ||
| D | $38,116 | COST |
| OF CANADA | ||
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | SCHEDULE R | FormAndLineReferenceDesc |
| Explanation | THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA CARRIES OUT THE SAME PRIMARY ACTIVITIES AS THE LEUKEMIA & LYMPHOMA SOCIETY, INC., IN CANADA. THE LEUKEMIA SOCIETY RESEARCH PROGRAMS, INC. AND THE LEUKEMIA RESEARCH FOUNDATION, INC. SUPPORT THE ACTIVITIES OF THE LEUKEMIA & LYMPHOMA SOCIETY, INC. | ExplanationTxt |
Comments